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ABSTRACT
The brain accounts for 20% of overall energy metabolism in the body though it
just comprises 2% of the total body mass but has a limited capacity of storing energy
unlike other critical organs in the body such as the heart and liver. This energy along with
oxygen and nutrients is supplied by cerebral blood flow (CBF), any interruption of which
can cease the brain function within seconds with a potential irreversible neuronal injury,
within minutes. Vascular cells along with astrocytes and neurons are a part of a recently
developed concept known as the Neurovascular Unit responsible for Neurovascular
coupling (NVC), a phenomenon whereby an increase in neuronal activity leads to
elevation of local CBF. The blood-brain barrier(BBB) chiefly composed of the vascular
cells and astrocytes comprises the major role in NVC and thus is central to understanding
brain functions and disorders.
Nitric oxide (NO) is a calcium-dependent vasoactive mediator that heavily
influences NVC while intracellular calcium (Ca++) is a second messenger that serves for
complex signaling roles in the brain. Impairment in the homeostasis of these signals can
lead to extreme functional alterations in the brain. Furthermore, both NO and Ca ++
changes have been shown to affect BBB permeability which is a common feature
observed in many neurological disorders. Therefore, this research investigates the
alteration of NO and Ca++ signals in the rat brain microvascular endothelial cells
(BMVECs) and astrocytes, the two major cell types of BBB during inflammation, and
further evaluates the effect of cellular interaction between them in modulating these
iii
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signals by developing their co-culture model. It focuses on phenotypic and biochemical
changes in BBB due to inflammation, as inflammation related failure of BBB is
implicated in the initiation or progression of a wide variety of neurological disorders.
Both NO and Ca++ were found to increase excessively in BMVECs unlike the astrocytes
during inflammation, and in the co-culture model, the presence of astrocytes was found to
provide negative feedback to these elevated NO and Ca++signals from BMVECs.
Considering the dominant role of NO and endothelial cells in NVC, this research
investigates a potential application of a novel material, copper -cystine biohybrid known
as Copper High Aspect Ratio Structures (CuHARS) in catalyzing NO in BMVECs in
normal as well as in induced inflammatory conditions. CuHARS was able to increase the
NO concentration in normal BMVECs by stimulating endothelial nitric oxide synthase
(eNOS) activity, known to have neuroprotective roles besides inhibiting the usually
harmful NO synthesis in an inflammatory condition. Thus, CuHARS displays potential in
therapeutic applications for NO related NVC disorders in addition to the antimicrobial
and wound healing applications studied earlier.
The tight junctions, unique to the endothelial lining of the brain, limit the entry of
drugs against neurological and mental disorders from reaching into the brain. This poses
an immense challenge in developing treatments for brain disorders. This research
explores the naturally available Halloysite nanotubes (HNTs) for drug loading and
delivery across the BBB. HNTs loaded with a fluorescent dye (RITC) and ionomycin
separately were tested on BMVECs to study periodic and real-time attributes of HNTs in
drug delivery. HNTs were found to deliver the payload gradually over an extended period
to the BMVECs cells.
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INTRODUCTION

1.1

Background and Motivation

Neurological disorders are reported to be the second leading cause of death
globally after heart disease. They account for 16.5% of death, and are the leading cause
of disability with 11.6% global disability-adjusted life year (DALYs) by the Global
Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 which included studies
from 1990 to 2016 for 195 countries (1). Alzheimer’s disease, Epilepsy and seizures,
Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), Brain Tumors, Multiple sclerosis,
stroke, and headache are common neurological disorders. The treatment of these and
other diseases of the central nervous system (CNS) are rendered difficult by the
physiologic, metabolic and biochemical obstacles, mainly the blood-brain barrier (BBB)
and the blood-cerebrospinal fluid barrier (BCFB). The brain, being a crucial organ, has
capillary microvessels which possess a unique feature termed as BBB that limits the
influx and efflux of molecules and cells between blood and brain preventing the toxic and
infectious agents circulating in the blood from getting into the brain (2,3). The
endothelial cells of the brain are referred to as brain microvascular endothelial cells
(BMVECs). They provide the relative impermeability of the BBB which results from the
tight junctions and adherens junction between these cells formed by cell adhesion
molecules. The structural and functional integrity of BBB is maintained by close
1
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apposition of endothelial cells and astrocyte endfeet, with endothelial cells lining the
luminal side and astrocyte endfeet wrapping around 99% of the abluminal side of the
basement membrane in the BBB (4) as shown in Figure 1.1. The integrity of BBB allows
it to control the brain homeostasis as well as ion and molecule movements, and disruption
of BBB leads to cellular damage in neurological disease, including cerebral ischemia,
multiple sclerosis, brain tumors, brain infection, and brain trauma (5).

Figure 1: Schematics of blood brain barrier (BBB) showing features and
orientation of cells involved in forming the BBB structure (6).
Inflammation is the fundamental biological response of the body against injury
and infection to remove the cause and effect of cell injury and to initiate cell repair, but
chronic inflammation can lead to tissue damage and inappropriate immune response,
unlike the beneficial acute response. Prolonged inflammation in the brain or CNS can be
explicitly injurious and contribute to the pathogenesis of Alzheimer’s, Parkinson's,
Multiple sclerosis, ischemia, traumatic brain injury, depression, autism, and some
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epileptogenesis (6,7). Neuroinflammation and BBB disruption are often related and are
extensively being studied causes of a wide variety of neurological disorders (8–13).
This research focuses on developing an in vitro co-culture model of the two major
cell types of the BBB, BMVECs and astrocytes. The work and studies the inflammationinduced morphological and signaling responses, specifically nitric oxide (NO) and
intracellular calcium concentration (Ca++), in the monoculture and co-culture of these cell
types to get a deeper insight on the phenotypical and biochemical response of endothelial
cell-astrocyte interaction, which is expected to explain several aspects of BBB behavior
in response to inflammation. In addition, this research also investigates the potential of
the novel material Copper High Aspect Ratio Structures (CuHARS) (14,15) in altering
the nitric oxide response during inflammation and normal physiological conditions in the
BMVECs cells considering the significant role of NO in neurovascular coupling.
The selective permeability of BBB imparted by the tight junctions of endothelial
cells provides a natural defense mechanism against toxins and bacteria and prevents the
drugs against neurological and mental disorders from crossing the barrier to reach the
brain (16). Overcoming the BBB for drug delivery is a major challenge in the treatment
of neurological and mental disorders, and the use of nanotechnology for the development
of therapeutics against brain disorders has been attracting increasing research interest.
Nanoparticles are versatile and promising drug delivery systems for inaccessible regions
like the brain with the benefits of protection, encapsulation, and efficient delivery of
therapeutic agents to the targeted area (17). Therefore, this research explores the potential
of halloysite nanotubes (HNTs) as a drug delivery vector across BBB (18,19).
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1.2

Research Goals

The phenotype of the blood-brain barrier is influenced by associated brain cells,
specifically the astrocytic glial cells. These cells are involved in two-way
communication. The close apposition of astrocytes to endothelial cells is thought to be
necessary for the development and maintenance of the BBB junction proteins. The brain
endothelium enhances the growth and differentiation of associated astrocytes while
astrocytes release chemical mediators that modulate the barrier permeability over a time
scale of seconds to minutes in addition to the long-term barrier induction and
maintenance (14). Astrocytes occupy a strategic position between endothelial cells, and
neurons and the endfeet that help form the BBB are especially involved in ionic, amino
acid, neurotransmitter, and water homeostasis in the brain. Signals arising within the
brain, rather than a programmed commitment of the endothelial cells, are known to be
responsible for the expression of barrier properties (15). Therefore, this project aims to
develop a co-culture model of primary brain microvascular endothelial cells (BMVECs)
and astrocytes in vitro to study the cellular interaction in the BBB. Specifically, the
effect of co-culture on NO and calcium response is studied, as these are the signals that
dominate in the brain during inflammation. The co-culture will also be tested for the
toxicity, uptake, and delivery properties of novel materials such as CuHARS and
biofriendly nanotubes-HNTs to investigate these particles as potential carriers for drug
delivery across the BBB. The hypotheses of this study are stated below.
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Hypothesis 1
BMVECs produce excessive NO during inflammation and cellular interaction between
astrocytes, and BMVECs provide negative feedback to this excessive NO produced by
BMVECs.
Hypothesis 2
Copper High Aspect Ratio Structures (CuHARS) can increase NO release from BMVECs
by catalytic action in the presence of S-nitrosocysteine (CysNO), an NO precursor found
in the blood. This capacity for NO catalysis indicates its potential for therapeutic
applications for brain conditions related to Neurovascular Coupling (NVC) disorder.
Hypothesis 3
Treatment of BMVECs with NO donor (sodium nitrite) in the presence of d-serine, a coagonist for glutamate receptor NMDA, enhances (Ca++) activity and causes calcium
oscillations in the BMVECs.
Hypothesis 4
Inflammation leads to calcium dysregulation in BMVECs, and astrocyte cells can provide
a negative feedback mechanism to the dysregulated calcium activity in BMVECs during
inflammation.
Hypothesis 5
Naturally available halloysite nanotubes (HNTs) can be a vehicle for targeted drug
delivery across BBB for potential treatment of neurological disorders.
1.3

Dissertation Overview

Chapter 1 discusses the background and motivation for research, research goals,
and hypotheses for the project, and the flow of the dissertation. Chapter 2 lays out the
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background and literature review on befitting research work involving cellular interaction
between BMVECs and astrocytes, neurological disorders related to inflammation and
BBB dysfunction, NO and Ca++ signaling in the brain, their physiological and
pathological roles in the brain, and their respective role in BBB permeability. Chapter 3
describes the technique of developing a mixed co-culture model consisting of BMVECs
and astrocytes to mimic the BBB microenvironment and the characterization and
evaluation of the coverage by each cell type in the co-culture model. Chapter 4 elucidates
the role of astrocytes in providing negative feedback to the nitric oxide production in
BMVECs during inflammation. It underlines the NO production from individual cultures
and from co-culture models while it highlights the morphological changes caused by
inflammation in cellular networks. Chapter 5 addresses the application of copper-cystine
biohybrid well known as CuHARS in catalyzing NO production from normal BMVECs
in the presence of a NO precursor normally found in blood. The chapter further explores
CUHARS’ ability to alter NO produced by induction of inflammatory conditions in
BMVECs. Chapter 6 discusses the effect of NO donor in calcium activity of the
BMVECs cells and contemplates the role of astrocytes in modulating calcium
dysregulation in BMVECs during inflammation by studying calcium activity in
individuals and the co-culture model. Chapter 7 presents the potential application of
HNTs for drug delivery across the blood-brain barrier. Finally, Chapter 8 provides the
overall conclusions and future directives for the research.

BACKGROUD AND LITERATURE REVIEW

2.1

Blood-Brain Barrier

The blood-brain barrier (BBB), as the name suggests is a barrier between the
brain’s blood vessels and the cells or other components that make up brain tissue. BBB
has been identified as a complex and dynamic system involving biochemical and
biomechanical signaling between the vascular system and the brain (20). The brain
capillaries permeate the brain with a total length of approx. 600 km, total capillary
surface area for membrane transport of 20 m 2 and a mean transport distance of 40 µm.
These dimensions suggest that almost every neuron in the brain is supplied with its own
capillary (21). BBB constitutes the endothelial cells of the capillary wall, astrocyte
endfeet that ensheath the capillary, and the pericyte cells embedded in the capillary basal
membrane (22). These anatomic substrates of BBB constitute a neurovascular unit
(NVU) which is central to neurovascular coupling (NVC) as shown in Figure 2.1. NVC
is an essential phenomenon for the health and function of CNS. NVC is a relatively new
concept that links a transient neural activity to a corresponding increase in cerebral blood
flow (23,24).
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Figure 2. 1: Schematic of a neurovascular unit. Left: The neurons and astrocytes are in
close apposition to the endothelial cells. Right: Neurovascular coupling highlighting
energy exchange in between these cells (25).
2.1.1

Brain Microvascular Endothelial Cells (BMVECs)
The BMVECs are highly specialized cells. The BBB requires such specialization

because it is the major site of blood-CNS exchange (26) that maintains homeostasis of
ions, nutrients, and other essential molecules for proper brain function (27). The presence
of intercellular tight junctions and a thick continuous glycocalyx (a layer made of
proteoglycans and sialoproteins that lines apical endothelium) along with the absence of
fenestra, and a scarcity of pinocytic vesicles are unique characteristics of these cells that
allow for the selective permeability between the systemic circulation and the extracellular
fluid compartments in the brain (28). These features make BBB an effective organ for
preventing unwanted substances such as toxins, bacteria, and other foreign materials in
blood from accessing the brain, but it comes with a pitfall. It also prevents most potential
drugs for neurological and mental disorders from readily crossing the barrier and
reaching the brain, posing an immense impediment to the treatment of brain disorder. The
tight junctions (TJs) and adherens junctions (AJs) primarily determine BBB properties.
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While TJs seal the inter endothelial cleft AJs initiate and maintain endothelial cell to cell
contact. Both junctions are composed of transmembrane proteins and cytoplasmic plaque
proteins (29). Figure 2.2 shows the cell morphology of primary rat BMVECs cultured in
vitro, depicting the feature of lumen which are the tubular structures formed in some
endothelial cultures when they reach confluence.

Figure 2. 2: A) Phase contrast image of in vitro culture of rat BMVECs showing
morphology with characteristic lumen formation in between the cellular network B)
DAPI stained image of BMVECs, networking to form a lumen C) Diff Quik
stained image of BMVECs showing distinct nuclei and cell body of the cells. Scale
bar= 100µm,Magnification =200X.
2.1.2

Astrocytes
Astrocytes (Figure 2.3) are the most abundant glial cells in the central nervous

system, outnumbering neurons nearly fivefold (30). Astrocytes occupy a strategic
position in between neurons and capillaries and play a crucial role in ionic, amino acid,
neurotransmitter, and water homeostasis of the brain specifically by the ones that form
perivascular endfeet. The astrocyte endfeet are specialized processes that extend from
its cell body to the basement membrane and surround the endothelial and pericyte
cells. They cover the basement membrane surface area for a range of 80 to 99% of the
CNS microvasculature. It also extends from the cell body to the neurons and thus
provides for the bidirectional signaling between neuron and vasculature, which
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coordinates blood flow with the neuronal activity (31). Factors secreted by astrocytes
play an important role in the formation and maintenance of BBB by providing a requisite
association between BBB cells and the formation of strong TJs (32). The proximity of
endothelial cells to astrocytes suggests key roles of astrocyte-derived factors in BBB
disruption and recovery after brain damage (4).

Figure 2. 3: Fluorescence microscopy image of rat astrocyte stained against the glial
fibrillary acidic protein (GFAP) showing star-shaped astrocyte with multiple processes
networking with surrounding cells. Scale bar=100 µm, Magnification =200X.
2.2

Co-culture of BMVECs and Astrocytes

The brain microvascular endothelial cells (BMVECs) differ from the endothelium
of peripheral capillaries in the presence of complex tight junctions, absence of fenestra,
limited pinocytic transport, and a continuous basement membrane that limits the
permeability of molecules from the blood into the CNS (33). They also express a wide
span of efflux pumps on their laminar surface that prevents the uptake of lipophilic
molecules including drugs (34). Astrocytes provide signals for differentiation of the
BMVECs and are essential in maintaining BBB integrity in vitro and in vivo (4,34). A coculture model of BMVECs with astrocytes provides an excellent technique to study
cellular interactions between these two different cell types in BBB as the monocultures
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may not accurately resemble the physiological relevance in the in vivo studies. The
mixture provides a better insight into heterotypic cell-cell interactions (35). Moreover,
astrocytes occupy a strategic position in between neurons and the capillaries and evidence
suggests that signals from the brain, rather than a programmed commitment of BMVECs,
are responsible for BBB properties (36). Astrocyte-derived factors are implicated in BBB
disruption and recovery after brain damage. Vascular endothelial growth factor (VEGF),
NO, glutamate, endothelin-1, and matrix metalloproteinases are astrocyte-derived
vascular permeability factors that enhance BBB permeability and might lead to BBB
disruption. In contrast,angiopoietin-1, glial-derived neurotrophic factor, retinoic acid
insulin-like growth factor, and apolipoprotein E are the astrocyte-derived protective
factors that can attenuate BBB permeability resulting in the recovery of BBB functions
(4). Growing these two cell types together provides a characteristic morphological
organization that is analogous to enzyme induction and tight junction comparable to in
vivo (36).
Figure 2.4 illustrates a schematic diagram of BMVECs alone , and astrocytes
alone, obtained from rat cortical tissue, put together in a co-culture model.
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Figure 2. 4: Schematic representation of A) normal rat brain astrocytes; B)
endothelial cells (BMVECs); C) co-culture of normal rat brain endothelial cells and
astrocytes.
2.3

Neurological Disorder in Relation to Inflammation and BBB Dysfunction
Diseases of the central and peripheral nervous system (PNS), which affect the

brain, spinal cord, peripheral nerves, cranial nerves, nerve roots, autonomic nervous
system, neuromuscular junctions, and muscles are defined as neurological disorders
(37,38). Epilepsy, multiple sclerosis, ALS, stroke, and traumatic brain injury are some of
the neurological disorders, each of which affects the CNS differently, but studies have
suggested that they share common defects in the BBB (39). Disruption of BBB has a
significant role in cellular damage in brain tumors, acute and chronic ischemia, brain
infections, and neurodegenerative diseases. Inflammation is a biological response to
injury and infection to mitigate the cause of injury and initiate healing or repair. The
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acute inflammatory response is normally beneficial and ends at healing, but chronic
inflammation can lead to tissue damage and inappropriate immune response (6). During
inflammation, the changes at the BBB are mainly related to two-modes of action: 1) BBB
disruption that describes the leakage and alteration of TJ components and ii) BBB
activation, which implies the capacity of BBB cells to express and secrete immune
factors that can influence the recruitment and effector functions and the survival of
immune cells entering the brain (40). A cascade of molecular events during injury leads
to an ultimate common pathway of BBB disruption caused by proteases and free radicals
of oxygen and nitrogen that attack and degrade the tight junction proteins in BMVEC
cells. These free radicals and proteases play a vital role in the early and delayed
disruption of BBB as the neuroinflammatory response progresses. A compromised BBB
contributes to cognitive changes in neurodegenerative diseases (5). Besides its crucial
role in injury, the BBB as part of NVU plays an important part in angiogenesis, which
helps in the recovery process. Therefore, identification of cellular and molecular events to
prevent BBB disruption without hindering the recovery mechanisms is a major challenge
in treating neurological disorders in addition to the usual course of facilitating drug
delivery.
2.3.1

Multiple Sclerosis (MS)
MS is an ideal example of inflammatory disease of the CNS which is

characterized by the destruction of the myelin sheath. MS is an autoimmune disease
initiated by T- cells that attack the myelin which is escalated by the inflammatory
response due to microglia and macrophages (6). Disruption of BBB and trans endothelial
migration of activated leukocytes, along with the release of inflammatory cytokines, are
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some of the earliest abnormalities seen in MS (12). Breakdown of BBB is thought to be
transient in MS, though recurrence may be observed within weeks, months, or even
years. The subsequent progression and lesion development in MS involves secondary
phases of BBB leakage and demyelination mediated due to immune responses and
various degrees of axonal injury (41).
2.3.2

Alzheimer Disease (AD)
AD is a widely recognized chronic progressive neurodegenerative disease. With

pathological features of focal extracellular deposits of fibrillar amyloid β peptide (Aβ)
and intracellular tangles of hyperphosphorylated tau proteins in the brain, it also causes
dementia (42,43). Pathogenesis of this disease involves interaction with immune
mechanisms in the brain with an elevation of inflammatory cytokines, acute-phase
proteins, and complement components along with signs of activated microglia and
astrocytes locally in the regions where Aβ deposits as foci (6). Reduced expression of TJ
proteins, reduction in capillary length suggesting endothelial degeneration, and capillary
basement membrane changes have been reported from brain tissue of patients with AD.
Dysregulated intracellular [Ca++] homeostasis and BBB damage have been implied in the
pathogenesis of AD (44).
2.3.3

Parkinson’s Disease (PD)

PD is the second most prevalent neurodegenerative disease, with pathologic features of
progressive death of dopaminergic neurons in the substantia nigra (midbrain region that
modulates motor movement and reward functions) and intracellular accumulation of αsynuclein protein-rich Lewy bodies. PD is a multisystem disorder and neuroinflammatory
responses that activate microglia and astrocytes assist in BBB infiltration causing
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neurovascular dysfunction which in turn is an important pathway leading to loss of
dopaminergic neurons (45). Disruption of BBB increases the susceptibility of neurotoxic
substances to dopaminergic neurons and immune system mediators that contribute to PD
progression (46).
2.3.4

Epilepsy
Epilepsy is the fourth most prevalent neurological disorder characterized by

recurrent and unpredictable seizures that might be caused by brain injury or heredity (47).
BBB disruption encourages seizures, favors seizure recurrence, and contributes to
epileptogenesis. The electrophysiological viewpoint suggests that BBB disruption results
in serum albumin penetration to the brain, loss of water, and dysregulation of glutamate
and potassium, ultimately altering the brain microenvironment and neuronal functions
(48). During inflammation leukocyte binding at the endothelium initiates BBB
dysfunction, which causes increased permeability to ions and proteins, edema, and
changes in the brain microenvironment. Proinflammatory stimuli are indicated to cause
seizure promoting communication between the periphery and brain. Inflammatory
stimuli, including lipopolysaccharide (LPS), upregulate monocyte chemotactic protein
which causes an increase in BBB permeability (49).
2.3.5

Amyotrophic Lateral Sclerosis (ALS)
ALS is a neurodegenerative disease that results in progressive loss of motor

neurons, thus causing muscular paralysis and death mostly within 2-5 years of diagnosis
(50). ALS occurrence is mostly implied to a composite syndrome with irregular
pathways, but neuroinflammation is a major facet of ALS pathology(50). Activation of
glial cells by inflammation is a well-known feature of ALS, while immune cells like mast
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cells and T cells enhance cytokine production that facilitates the entry of immune cells,
including the mast and T cells themselves, when the barrier integrity is compromised. As
is seen in other neurodegenerative diseases, oxidative stress-induced reactive free radicals
at brain endothelial cells can cause a hyperpermeable BBB that allows a wider range of
molecules to pass through, resulting in a more dreadful and faster progression of ALS
disease (51).
2.3.6

Traumatic Brain Injury (TBI)
TBI is defined as the disruption in normal brain function, possibly caused by a

blow, bump, or jolt to the head, or penetrating head injury (52). While mild TBI may
cause only temporary dysfunction, severe injury can cause bruising, bleeding, damaged
tissues, and other physical insults to the brain followed by secondary pathological
progressions such as ischemia, neuroinflammation, and excitotoxicity that might lead to
long term complications or death (53). In both the adult and the developing brain, one of
the first responses to injury is the degranulation of mast cells which might facilitate the
BBB breakdown (54). Growing evidence suggests that the ischemic, hemorrhagic, or
traumatic brain injury leads to BBB breakdown which is thought to be responsible for the
death of neural tissue and to affect response to neuroprotective drugs. Brain inflammatory
response to injury is a significant part of TBI pathophysiology. There is an upregulation
of proinflammatory cytokines like TNFα and IL1- β followed by increased release of
chemokines and cell adhesion molecules on an endothelial surface that increases leakage
of inflammatory cells from blood to the brain. (55)
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2.3.7

Cerebral Ischemia
Cerebral ischemia refers to a lack of oxygen supply in the brain, caused by

blockage in an artery, that leads to damage of brain tissues (56). It is responsible for 80%
of the total strokes, where the rest (20%) are due to cerebral hemorrhage. Stroke (a form
of cerebral ischemia) is the most frequent cause of disability, the second most common
cause of dementia, and the fourth most common cause of death in first world countries
(57). Pathology of stroke is characterized by inflammatory responses like microglial
activation, cytokine or chemokine release, and neutrophils and macrophages infiltration
(58). Activation of mast cells is another important feature of ischemic injury. Ischemia is
accompanied by BBB breakdown, allowing for immune-inflammatory cell influx into the
brain. Mast cells occur on the brain side of BBB and enhance its breakdown. Further,
BBB disruption can result in alteration of hyperpermeability and extravasation of
leukocytes into brain tissue, resulting in edema formation in neuropathological disorders,
including stroke (59).
It is obvious from the above descriptions of the variety of neurological disorders
that research relating to inflammation and BBB disruption had been biased against the
role of microglia and astrocyte during brain inflammation while endothelial cells, though
being a major part of NVU and the BBB have been left out by most of the studies.
Therefore, this research attempts to fill the gap of information related to inflammatory
changes in the BMVECs and the effect of their cellular interactions with astrocytes in the
co-culture system specifically to the biochemical signals NO and [Ca ++].
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2.4

Cell Signaling Molecules

The molecules that help the cells communicate between or within themselves are
known as cell signaling molecules. Though typically these molecules act as ligands that
bind to the receptors expressed by target cells, a large variety of structurally and
functionally different types of molecules serve in cell signaling. Structurally they range
from simple gases to proteins. Some molecules carry the signal over long distances and
are called endocrine signals, while some act locally to affect the behavior of surrounding
cells and are called paracrine signals. Some major types of signaling molecules are
discussed below.
2.4.1

Hormones

Hormones are major endocrine signaling molecules, which come in two varieties.
i)

Steroid hormones are lipid-soluble molecules that interact with receptors in
the cytosol or nucleus of cells such as estrogen and progesterone.

ii)

Peptide hormones are water-soluble molecules that bind to cell surface
receptors such as insulin, growth factors, and glucagon.

2.4.2

Gaseous Molecules

2.4.2.1

Nitric Oxide (NO)

NO is a gaseous molecule and is a major paracrine signaling molecule in the nervous,
circulatory, and immune system of body. NO diffuses freely across the plasma
membranes of the target cells like the steroid hormones, however its mode of action is
different in that it acts directly on the intracellular target enzymes rather than binding to
the receptors that regulate transcription. NO is synthesized by an enzyme nitric oxide
synthase (NOS) from the amino acid L-arginine (Figure 2.5). Two forms of endothelial
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NOS, constitutive (cNOS) and inducible (iNOS), synthesize NO during normal
physiological conditions and inflammation respectively. A third form of NOS, neural
NOS (nNOS) acts as a neurotransmitter in the CNS and peripheral nervous system (60).
Though NO is produced under physiological condition through oxidation of L-arginine,
L-arginine is not a limiting factor for the reaction, as NO can be synthesized from
citrulline or glutamic acid, but when iNOS is active for a long time, L-arginine becomes
depleted, causing iNOS to produce superoxide anion (O2-) (61).
NO is a key signaling molecule in the dilation of blood vessels. The process
initiates after the release of neurotransmitters like acetylcholine from the nerve terminals
in the wall of blood vessels. These neurotransmitters stimulate NO synthesis from the
endothelial cells that diffuse to nearby smooth muscle cells (SMCs) as shown in Figure
2.6, where it acts on the enzyme guanylyl cyclase to increase the second messenger cyclic
GMP (guanosine monophosphate) that induces SMCs relaxation and thus results in vessel
dilation (62).

Figure 2. 5: Synthesis of NO by NOS from catalysis of amino acid Arginine (63).

20

Figure 2. 6: NO signaling pathway for blood vessel dilation between endothelial and
smooth muscle cells. R : Receptor, L-arg :L-arginine, cNOS: constitutive nitric oxide
synthase, GC: Guanylyl cyclase, GTP: guanosine triphosphate, cGMP: cyclic
guanosine monophosphate(60).
2.4.2.2

Carbon monoxide (CO)
Carbon monoxide (CO) is another gaseous molecule that functions as a signaling

molecule in the nervous system. Like NO, it’s synthesis in the brain is also stimulated by
neurotransmitters, and it also acts as a mediator for vasodilation (62).
2.4.3

Neurotransmitter
Neurotransmitters are the chemical messenger that carry signals between neurons

or between neurons and other target cells across chemical synapses such as muscles. The
size of a neurotransmitter varies from a single amino acid to large proteins or peptides.
Neurotransmitters constitute a great variety of hydrophilic molecules such as glutamate,
γ-aminobutyric acid (GABA), dopamine, epinephrine, serotonin, histamine, and glycine
(64). Classical neurotransmitters are packaged and stored in synaptic vesicles once
synthesized by the presynaptic neuron. Neurotransmitters are released at the synaptic
cleft when the threshold action potential is reached (65, 66), where they bind with
receptors in the postsynaptic terminals (Figure 2.7).
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Figure 2. 7: Neurotransmission at the synaptic cleft between the presynaptic and
postsynaptic neurons (67).
2.4.3.1

Glutamate
Glutamate is the most abundant free amino acid and the main excitatory

neurotransmitter in the brain. It is the principal mediator of nervous system plasticity and
is at the crossroad of multiple metabolic pathways (63,65). It is implicated to be vital in
modifying synapses that are believed to be essential for learning and memory.
Glutamate is able to elicit cell death through its unregulated excitatory effect on neurons,
and the process is referred to as excitotoxicity. Glutamate uptake systems strongly
dominated by astrocytes prevent excessive activation of glutamate receptors by
continuous removal of glutamate from the extracellular fluid in the brain. Moreover, the
BBB defends the brain from glutamate in the circulating blood (66). Most of the cells in
the nervous system express at least one of the several types of glutamate receptors (68).
Glutamate receptors have been classified as N-methyl-D-aspartate (NMDA), α-amino-3hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate receptors, and
metabotropic receptors. Overactivation of NMDA receptors resulting in excessive Ca ++

22
influx is one of the major causes of excitotoxicity (69,70), which is implicated in epilepsy
and some neurodegenerative diseases like AD, PD, and Huntington’s disease (71–73).
2.4.3.2

GABA
GABA accounts for about 40% of the inhibitory processing in the brain and

therefore serves as a major inhibitory neurotransmitter in the brain. Its primary function is
to reduce neuronal excitability throughout the nervous system (64).
2.4.4

Cytokines
Cytokines are small proteins secreted by cells that help in cellular interactions and

communications in the immune system. Interleukins (cytokines made by leukocytes that
act on other leukocytes), chemokines (cytokines with chemotactic activities),
lymphokines (cytokines made of lymphocytes), and monokines (cytokines secreted by
monocytes) are the different classes of cytokines. They might be autocrine, paracrine, or
endocrine in function. There exist both proinflammatory and anti-inflammatory
cytokines. Proinflammatory cytokines such as IL-1β, IL-6, and TNF-α are released
primarily by activated macrophages and assist in up-regulating the inflammatory
reactions (74).
TNF-α, also identified as cachectin, is produced mainly by macrophages or
monocytes during inflammation, which makes up the acute phase reaction, but if
unchecked, it can elicit chronic and acute diseases that may be both infectious and noninfectious (75). TNF is primarily responsible for regulating immune cells and it can
induce fever, inflammation, cachexia or apoptotic cell death. It can also inhibit
tumorigenesis, viral replication, and sepsis via IL-1and IL-6 releasing cells. TNF is
produced in large quantities by human monocytes when triggered by lipopolysaccharide
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(LPS), an endotoxin from bacteria (76). TNF dysregulation has been implied as a
hallmark of acute and chronic neuroinflammation along with many neurodegenerative
diseases such as AD, PD, ALS, MS, and ischemic stroke (77).
2.5
2.5.1

Nitric Oxide Signaling in Brain

Physiological Roles of NO
NO plays a vital role in intracellular signaling in neurons from modulating

neuronal metabolic status to dendritic spine growth, serving as the retrograde
neurotransmitter in brain synapses and regulating cerebral blood flow. Further, it is also
an important player in regulating protein functions, as it can execute post-translational
modification in proteins by S-nitrosylation of thiol amino acids (61,78). S-nitrosylation of
proteins is a secondary pathway by which NO can influence CNS neurotransmission (79).
The significance of NO as a neuromodulator or an intermediary signal in the brain is
underlined by the fact that glutamate, the most abundant amino acid in the brain and the
excitatory neurotransmitter, is an initiator of the reaction that produces NO (78,80). As
seen in Figure 2.8, glutamate, when released in synapses, activates the NMDA receptors
allowing Ca++ influx in the postsynaptic neurons, which activates nNOS, producing NO.
Thus released NO acts on presynaptic neurons (retrograde neurotransmission) where it
stimulates the release of GC-independent mechanism of glutamate exocytosis from a
presynaptic neuron which results in long term potentiation (LTP), the physiological
mechanism of learning and memory (61,81,82). LTP induces the dendritic spine growth
by activating cAMP-response element-binding protein (CREB), which activates the gene
expression related to learning and memory (81).
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Figure 2. 8: NO signaling pathway as retrograde neurotransmitter and facilitator of
LTP (61).
2.5.2

Pathological Roles of NO
Though NO serves a wide variety of physiological roles, it can be harmful and

toxic to the brain during pathological processes and aging when it reacts with free
radicals like O2- to form peroxynitrite (ONOO−). Peroxynitrite is formed when NO reacts
with O2- and is a vigorous oxidant that results in a broad variety of tissue-damaging
effects such as enzyme and ion channel inactivation. The inactivation occurs due to
protein oxidation or nitration, lipid peroxidation, and inhibition of mitochondrial
respiration by peroxynitrite (82). O2- can easily diffuse throughout the membrane and
damage proteins, lipids, and nucleic acids of neurons. In proteins, it mostly reacts with
the tyrosines to form nitro-tyrosines which affect the physiological functions of proteins
dramatically and irreversibly. This phenomenon of protein nitrotyrosination leads to the
agglomeration of modified proteins contributing to the initiation and progression of
neurodegenerative diseases such as PD and AD (61).
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NO has a dual role in the immune system. Under physiological condition, NO is
anti-inflammatory as it impairs leucocyte influx through the capillary walls preventing
inflammation and working as an immune brake (83), but in both adaptive and innate
immune response, leukocyte activation leads to iNOS expression and the NO produced
contributes to inflammatory reactions by regulating cytokine release (84). NO regulated
inflammation is highly relevant in the brain as microglia, astrocyte, and endothelial cells
(85, 86), are found to express iNOS. Neuroinflammatory responses drastically increase
the risk of neurodegenerative diseases as was discussed in Section 2.3.
Moreover, the increase in NO caused by higher iNOS expression during
inflammation amplifies the chances of nitration. The brain has a high amount of
unsaturated lipids that serve as targets for oxidation and peroxidation, which makes it
susceptible to oxidative and nitrative damage that tends to increase with aging. AD and
PD exhibit the highest etiopathogenic relationship with nitrative stress (86–88) while MS,
ALS, and Huntington's disease show close association to oxidative stress and protein
nitrotyrosination (89–91). Because NO acts as a double edge sword through its numerous
physiological and pathological roles, it has a significant association in clinical medicine
and thus opens up new therapeutic opportunities (80).
2.5.3

NO and BBB Permeability
The selective permeability of BBB prevails due to the expression of multi-drug

resistant gene (MRD1) and multi-drug resistant associated proteins in the endothelial
cells, in addition to its unique features of presence of tight junctions, absence of fenestra,
and scarcity of pinocytic vesicles. NO has been implicated by many studies to mediate
the opening of BBB, ultimately resulting in vasogenic edema and secondary brain
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damage, though the precise molecular mechanism is not clearly understood (28,92).
Evidence from in vivo studies has suggested that NO itself can mediate a moderate
disruption in BBB but the disruption is greatly enhanced when treated with NO donor
producing several redox species of NO (93). The NO released from eNOS is thought to
have a protective effect because it is a vasodilator in BMVECs, but NO produced from
iNOS is a fraction of the biochemical cascade activated by inflammation or injury and
has been implicated in altering BBB integrity (94,95). The cytokines TNF, IL-1β,
interleukin-6, and interferon-γ, all of which induce expression of iNOS, have been shown
to modulate BBB integrity (94,95). The high volume of blood flow and exchange in
blood vessels makes them more prone to generate free radicals of NO and O 2-, which can
react to form (ONOO−) under pathological conditions like injury and stroke, thus leading
to oxidative damage of proteins, lipids, and DNA at the BBB and further induce toxicity
through nitrosylation of proteins (92). The NOS inhibitor NG‐nitro‐L‐arginine methyl
ester [L‐NAME] was found to inhibit the activation of matrix metalloproteinases (MMPs)
in rat ischemic models. MMP activation is a critical pathway for BBB opening as it can
hydrolyze TJ proteins and BBB extracellular matrix, leading to BBB opening (96,97).
Thus, those studies suggested NO mediated BBB opening through activation of MMPs.
2.6

Calcium (Ca++) Signaling

Ca++ impacts almost all aspects of cellular life. It is the simplest and yet most
versatile second messenger in biology (98). Second messengers are the molecules that
transmit the signal received at cell surface receptors like growth factors, cytokines,
neurotransmitters, and proteins. The functions of proteins are driven by their shape and
charge, and Ca++ binding to the protein alters the shape and charge of the protein. This
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ability of Ca++ to change the local electrostatic field and protein conformation is a
ubiquitous tool of signal transduction (99). The Ca ++ gradient is maintained at 10,000-fold
higher outside the cells compared to cytosolic free Ca ++ inside the cells (100). The vast
difference in the gradient controls the underlying speed and effectiveness of Ca ++. The
dramatic Ca++ changes within a cell are induced by voltage-dependent Ca++ selective
channels (VDCCs) which are the fastest Ca++ signaling proteins. Each VDCC can
conduct almost a million Ca++ ions/second down the 10000- fold gradient, and about a
few thousand channels can cause more than 10 fold changes in intracellular Ca ++ levels
within milliseconds (101).
Calcium signaling in cells occurs either through the gap junctions (connexin
channels) present in epithelia and cardiomyocytes or through transmitter-gated, ion
channels such as NMDA, nicotinic, and purinergic receptors. These transmitter-gated or
voltage-gated channels are a more common pathway of calcium signaling that can rapidly
increase periplasmic Ca++. This increase stimulates proteins that enables transmittercontaining vesicles to fuse to the plasma membrane and release molecules such as
glutamate, adenosine triphosphate (ATP), and acetylcholine, outside the cells onto
adjacent cell membranes (102). These calcium moderated events dominate most of the
neuroscience and are now appreciated in all cell types for extracellular communication
(99).
2.6.1

Calcium signaling in the Brain
Ca++ has a fundamental and versatile role in neuronal plasticity. It is a second

messenger for many signaling pathways in the brain such as energy production, neuronal
gene expression, synaptogenesis, synaptic transmission, membrane excitability, cell

28
survival, and processes central to learning and memory (103). Ca ++ influx in neurons is
regulated by VDCCs, NMDA receptors, or transient receptor potential (TRP) channels
located in the plasma membrane. In addition, inositol-1,4,5-triphosphate receptors
(IP3Rs) and ryanodine receptors can increase Ca++ level by mediated release from Ca++
stores in endoplasmic reticulum (ER) or sodium-dependent Ca ++ efflux from
mitochondria (104). Mitochondrial Ca++ controls ATP synthesis by regulating three Ca ++
sensitive dehydrogenases (pyruvate dehydrogenase, isocitrate dehydrogenase,
oxoglutarate) of the citric acid cycle. Besides, it shapes the spatiotemporal patterns of
Ca++ signals and is central in determining cell death and survival (105). Ca ++ from ER
controls a wide range of neuronal functions, from excitability of plasmalemma to
synaptic plasticity and modification of protein synthesis (106). The NMDA receptor,
upon binding to glutamate, permeates Na+ and Ca++. Na+ contributes to postsynaptic
depolarization while Ca++ causes Ca++ transients and ultimate physiological response.
The Ca++ influxes through NMDA or glutamate receptors are responsible for regulating
CREB dependent gene transcription (107) which is physiologically relevant to
establishing long-term synaptic plasticity and therefore to learning and memory.
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Figure 2. 9: Neuronal calcium signaling, showing sources of calcium influx and
efflux from the cell. Sources: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) and N-methyl-D-aspartate (NMDA) voltage-gated calcium
channels (VGCC), nicotinic acetylcholine receptors (nAChR), and transient receptor
potential type C (TRPC) channels. Mediators for calcium release from internal
sources inositol trisphosphate receptors (IP3R) and ryanodine receptors (RyR),
metabotropic glutamate receptors (mGluR). Mediators of Ca ++ efflux : plasma
membrane calcium ATPase (PMCA), the sodium-calcium exchanger (NCX), and the
sarco-/endoplasmic reticulum calcium ATPase (SERCA) metabotropic glutamate
receptors (mGluR) (107).
As Ca++ plays a central role in neuronal physiology, even a slight alteration of
Ca++ homeostasis results in extreme functional alteration. Disruption of Ca ++ homeostasis
is indicated in neurodegenerative and neuropsychiatric diseases, and normal aging
process despite their heterogeneous etiology(103).
2.6.2

Pathological Roles of Ca++ in Brain
Ca++ ion has been chosen as major intracellular signaling by evolution, possibly

from the moment when ATP came to be known as an energy substrate (108). During
aging and in neurodegenerative diseases, the mitochondrial aberration is related to
compromised energy production, apoptosis, and oxidative stress in cells (109,110).
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Evidence supports that crosstalk between Ca++ and redox signals play important roles in
brain physiology, but the redox signal promoted by oxidative and nitrosative stress causes
excessive Ca++ release and provokes a pathological response and neuronal death
(111,112). The high O2 consumption (~20% of O2 consumption in the body) of the
nervous system makes it prone to large quantities of reactive oxygen species (ROS)
formation. These species make it sensitive to oxidative stress caused by the enrichment of
unsaturated fatty acids in nerve cell membranes. Ca ++-dependent pathways regulate the
components of ROS homeostasis (113). Also, Ca ++ stimulates NO synthase that has been
shown to induce ROS generation during oxidative stress (105). ROS mediated oxidation
of nitrosium ions (NO+) releases RyR mediated Ca++ from the ER (114).
Ca++ dependent synthesis of free radicals was observed in response to β-amyloid (Aβ)
indicated for causing AD (115), and also was shown to be induced in neuronal death after
ischemia (116).
Neurodegenerative diseases, despite exhibiting a wide range of heterogeneity in
their appearance, show a prominent similarity in the molecular pathogenesis, as all of
them feature dysregulation in Ca++ homeostasis and signaling that involves alteration in
Ca++ regulating proteins through excitotoxicity, perturbed energy metabolism, alteration
in Ca++ buffering capacity, dysregulation of Ca++ channel activities, and oxidative stress.
Ca++ dysregulation can trigger cell death by activating proteases, caspases, or other
catabolic processes mediated by nucleases and lipases (105,117). Apart from
neurodegenerative diseases such as AD, PD, MS and ALS (118–121) disturbance in Ca ++
homeostasis leads to many other neurological diseases such as epilepsy, peripheral
neuropathies, dementia, cerebral ischemia, and psychiatric diseases like bipolar disorder
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and schizophrenia (122–125). Changes in Ca++ signaling pathways have also been
identified that underlie the progression of biological markers of aging (126,127).
2.6.3

Calcium and BBB Permeability
Permeability of BBB is principally governed by the TJs between endothelial cells,

and both high and low calcium levels have shown adverse effects on the cell to cell
contact of endothelial cells (128,129).
Ca++ activities affect migration of ZO-1tight junction protein from intracellular
sites to the plasma membrane (130), tight junction assembly (131), and electrical
resistance in endothelial and epithelial cells. Particularly, Ca++ regulation plays a central
role in TJ disruption between endothelial cells leading to an alteration in BBB
permeability (132–135). A decrease in Ca++ alters ZO-1-acting binding and changes the
intracellular localization of occludin whereas an increase in intracellular Ca ++ interferes
with TJ formation (131). Vasoactive agents such as histamine, endothelin, bradykinin,
and nucleotides such as ATP, adenosine diphosphate, and uridine triphosphate that are
known to increase BBB permeability also show calcium elevation (136,137). These
pieces of evidence suggest that Ca++ regulation in BMVECs is critical in moderating
BBB permeability.
Disruption of BBB is a key element in the pathogenesis of neurodegenerative and
neurological disorders, including epilepsy, stroke, AD and PD. Moreover, the capacity to
cross the BBB is a major consideration for targeted drug delivery in the brain. In vivo,
optical imaging in rat cerebral cortex showed that glutamate release, which is mostly
controlled by the Ca++ entry in neurons, increased vascular permeability which was
attributed to NMDA receptor activation. Endothelial cells also express NMDA receptors
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(138–140) as do neuron, astrocytes, and microglia. As shown in Figure 2.10, the
activation of these endothelial NMDA receptors by glutamate produces a Ca ++ influx that
results in Ca++ dependent NOS activation and thus NO release (141–143). Thus released
NO activates GC in endothelial cells to generate cGMP and increased levels of
intracellular cGMP results in a signaling cascade that leads to BBB opening by
rearranging TJ proteins away from cell-cell contact regions (141). Besides microglia can
also be activated by glutamate via NMDA receptors leading to NO production that might
further be activated following BBB opening thus creating positive feedback for BBB
disruption (144).

Figure 2. 10: A proposed mechanism for glutamate-induced BBB disruption by
Vazana et al. (2016) displaying that glutamate released from neurons can act on
endothelial cells via NMDA receptors on them to include Ca++ dependent NO release
leading to BBB opening (141).
Calcium modulates numerous downstream processes like protein phosphorylation
via protein kinase C (PKC) and ROS generation, both of which can regulate protein
activity and have been indicated in BBB disruption during an ischemic stroke (129).
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2.7
2.7.1

Assays

MTT Assay

MTT assay is used to evaluate the metabolic activity of the cells. As shown in Figure
2.11, the yellow-colored MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] is reduced to non-water-soluble purple formazan crystals in living cells. The
purple-colored crystals are dissolved in an organic solvent and converted into a colored
solution. The formazan products are then quantified using spectrophotometry at 595 nm.
The reduction of MTT provides a measure of cellular metabolism that correlates to
cytotoxicity. MTT can be reduced to formazan product only by the metabolically active
cells (145,146).

Figure 2. 11: Reaction scheme for MTT reduction (147).
2.7.2

NO Assay

The indirect determination of NO involves the spectrophotometric measurement of its
stable decomposition products NO3− and NO2−. This technique requires NO3− to be
reduced to NO2− first and then NO2− is quantified by using Griess reaction as shown in
Figure 2.12. Briefly, the Griess reaction is a two-step diazotization reaction in which the
NO-derived nitrosating agent, dinitrogen trioxide (N2O3) generated from the acid-
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catalyzed formation of nitrous acid from nitrite (or autoxidation of NO) reacts with
sulfanilamide to produce a diazonium ion which is then combined with N-(1-naphthyl)
ethylenediamine to produce a chromophore (azo product) that absorbs strongly at 540
nm. For quantification of NO3− and NO2− in extracellular fluids, the enzymatic reduction
of NO3− to NO2− using a commercially available preparation of nitrate reductase is a
satisfactory method.

Figure 2. 12: The dinitrogen trioxide (N2O3), nitrosating agent generated from
acidified nitrite (autooxidation of NO) reacts with sulfanilamide to yield diazonium
derivate, which will interact with N-(1-naphthyl) ethylenediamine to yield a colored
diazo product that absorbs strongly at 540nm (148).

DEVELOPMENT OF A CO-CULTURE OF PRIMARY
BMVECS AND ASTROCYTES AS A MODEL OF THE
BLOOD BRAIN BARRIER

3.1

Introduction

The brain is the center for an array of diverse physiological activities in the body
and it integrates signals received from the external environment with those from the
internal environment at the neuronal level to execute specific functions. The chemical
environment in which the brain cells operate needs to be strictly regulated which is the
fundamental function of the blood-brain barrier. The endothelial cells (BMVECs) line
the luminal side of the brain capillaries while the abluminal side is completely wrapped
around by a basement membrane, 99% of which is covered by the astrocytic end feet.
Evidence suggests that the direct contact between endothelial cells and astrocytes is at
least partially responsible for the development and maintenance of tight junctions
between the endothelial cells of BBB (107). The close apposition of astrocytes to
endothelial cells makes them an important participant of morphological homeostasis by
helping in the formation of BBB. Further astrocyte-derived factors such as NO, vascular
endothelial growth factor (VEGF), glutamate, endothelin-1 and matrix metalloproteinase
have been known to enhance BBB permeability, leading to its disruption, while
angiopoietin-1, glial-derived neurotrophic factor, retinoic acid, insulin-like growth factor,
and apolipoprotein E attenuate BBB permeability and recover BBB function (15).
35
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A co-culture model provides us with a propitious system to study cell to cell
interaction between a different population of cells in vitro. Most of the models studying
BBB permeability consists of a monolayer of endothelial cells, but often when cultured
alone, the endothelial cells once isolated from brain capillaries begin to lose their BBB
characteristics. Given this, we aim to develop a co-culture model of primary brain
endothelial cells and astrocytes to closely mimic the BBB microenvironment and study
the cellular interaction in between them and subsequently investigate the role of
astrocytes in providing a negative feedback mechanism to the two major signaling
molecules, NO and Ca++ when inflammation is induced in the BBB.
3.2
3.2.1

Materials and Methods

Cell Culture

Pregnant Sprague Dawley rat pups were sacrificed by cervical disarticulation between
post-natal day 1 – 3. All procedures were conducted according to a protocol approved by
the Louisiana Tech University Animal Care and Use Committee. Rat brain cortex was
obtained by dissecting the skull and moving it into a petri dish containing Basal Media
Eagle (BME, Sigma Aldrich) with 0.5% Penicillin Streptomycin (Sigma), where the
cerebellum, olfactory lobe, and meninges were removed. The cortical lobes were
collected in an F12 nutrient mixture containing 10% fetal bovine serum, 10% horse
serum, and other components (heparin, glutamine, NaHCO3) and stored on ice until
cortical tissue is obtained from an average of 7 pups. The cortical tissue is then aspirated
into a 15 ml tube consisting of astrocyte medium with Ham’s F-12K medium containing
5% Horse serum and 5% FBS (Appendix C.4) with a complementing volume of Trypsin
EDTA (volume determined by the number of pups used, Sigma), mixed by inverting at
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least 5 times and incubated for 10 minutes at room temperature. The media with trypsin
was pipetted out and fresh astrocyte media was added to the tissue. The tissues were then
mechanically dissociated by triturating 15 to 20 times and incubated for 10 minutes to
form a brain cell supernatant. This whole process of adding trypsin and then triturating is
repeated at least three times and each time the brain cell supernatant was collected and
stored in a 15 ml tube in an ice bath, which was then centrifuged to get a pellet of cells.
The cells were then cultured in a cell culture flask to get primary glial cell culture.
BMVECs were isolated from this primary culture by treating them with 5.5 μM of
puromycin dihydrochloride that kills all other cell types except the endothelial cells.
Endothelial cells are encoded with a puromycin N-acetyl transferase gene (PAC gene),
which confers resistance to the action of puromycin (28,144). Thus, isolated BMVECs
were then cultured in vitro at 5% CO2 and 37 °C in a rat endothelial growth medium (Cell
Applications Inc.) (Appendix C.3). Astrocytes were purified from the glial culture by
sub-culturing these cells and washing off the overlaying microglial cells a few times
before they are sub cultured.
3.2.2

Cell Characterization
The BMVECs were characterized by staining them against Von Willebrand

Factor (VWF), (Appendix G.3, Figure 3.2), an essential blood-clotting protein specific
to endothelial cells, and astrocytes were characterized by staining them against the glial
fibrillary acidic protein (GFAP), a cytoskeletal protein found specifically in glial cells.
(Appendix G.4, Figure 3.3).
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3.2.3

Co-Culture Model
Primary BMVECs and astrocyte were plated at a density of 20,000 cells each well

at the ratio of 1:1 in their respective growth media into the same well with direct cell-cell
contact in a 48-well cell culture plate (Greiner) and incubated at 5% CO 2 and 37 °C for
about 6-8 days until the confluency of cells in the wells reach ~ 80%.
3.2.4

Cell Fixation
After 6-8 days in vitro, the growth medium from the cells was aspirated and

washed with 300 µl of RPMI (Appendix F). To fix the cells, 250 µl of the 1X solution of
fixative was added such that it covered the entire well, and the plate was kept at room
temperature for 10 minutes. The cells were rinsed twice with 500 µL 1X PBS again.
3.2.5

GFAP Staining
To confirm normal in vitro characteristics and visualize cellular network in direct

contact between endothelial cells and astrocytes, astrocyte cells in the co-culture model
were stained using indirect immunofluorescence for glial fibrillary acidic protein
(GFAP). Cells were stained using Anti-Glial Fibrillary Acidic Protein (Anti-GFAP), an
antibody produced in the rabbit as 1° Ab from Sigma-Aldrich (Sigma Product #G9269),
and Alexa Fluo® 488 goat anti-rabbit IgG (H+L) as 2° Ab from Invitrogen Molecular
Probes (Invitrogen Product #A-11035) (Appendix G.4).
3.2.6

DAPI Staining
Nuclei for all cells were stained with 4,6-diamidino-2-phenylindole (DAPI) to

confirm cell viability and to visualize and identify the networks of astrocytes stained
against GFAP amongst the endothelial cells in a co-culture experimental model
(Appendix G.1).
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3.2.7

Microscopy
Microscopic images of the cells were recorded under a Leica DMI 6000B inverted

microscope. Phase-contrast images of the co-culture cellular networks were obtained to
identify morphological characteristics of each cell type in the direct contact network
which was followed by recording GFAP images of the cell culture model. GFAP staining
was viewed under fluorescence settings. For fluorescent imaging, a Leica EL6000 light
source was used. For GFAP imaging, excitation in the blue portion of the light spectrum
(~475 nm) was required. To view DAPI-stained nuclei, excitation light in the ultraviolet
range (~400 nm) was required. GFAP emits green light and DAPI emits blue light.
3.2.8

Image Analysis
The GFAP images captured through digital microscopy for the co-culture model

were analyzed using Image Pro-Plus version 7.0 developed by Media Cybernetics
(Rockville, MD). A mask was created to select the area covered by astrocytes on each
captured image from the co-culture model, as shown in Figure 3.1 and described in the
protocol (Appendix B). The area of the astrocyte cells present per image was analyzed
and saved to Microsoft Excel. The data thus obtained were used to compute the total area
covered by astrocytes per image, averaged over 3 images each well for 2 experiments
each with 4 wells.
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Figure 3. 1: Masking of image and measuring area covered by astrocytes in the coculture model using Image Pro 7 software.
3.2.9

Statistical Significance
A one-way ANOVA was generated with the multiple comparison method for

experiments consisting of more than two groups, and two-tailed t-tests were used to
compare two groups. The results were considered statistically significant when P < 0.05.
Data are presented as the mean ±standard error of the mean (SEM).
3.3
3.3.1

Results

Von-Willebrand Factor (VWF) Staining
To determine the purity of isolated BMVECs culture obtained from primary glial

culture, the cells were stained against VWF, a biomarker for endothelial cells (Figure
3.2). The cells were treated with primary and secondary antibodies as described by
protocol (Appendix G.3), and images were captured through digital microscopy after
staining. The images showed 100% staining of the culture, as shown in Fig 3.2B,
indicating the high purity of the culture, while the negative control cells (treated with
secondary but not the primary antibody against VWF), used for validation of the
technique showed no cell staining.
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Figure 3. 2: VWF staining for 10,000 cells per mL primary brain microvascular
endothelial cells. The left panel represents phase-contrast images, and the right panel
represents fluorescence images after VWF staining for the same region, VWF stained
BMVECs (A-B), and negative controls (C-D). Scale bar = 100 um, Magnification
=200X
3.3.2

GFAP Staining
For better visualization and to be able to distinguish and quantify the two different

BBB cell types used in this research, staining the cells was crucial. The astrocyte cells
were stained against GFAP, and images were obtained under phase contrast and
fluorescence microscopy. Figure 3.3 A demonstrates phase contrast images of normal
brain astrocytes. Only positive controls treated with primary and secondary antibody (1°
Ab + 2° Ab) (Figure 3.3 B) as mentioned in protocols (Appendix G.4) showed positive
results for GFAP staining while negative controls not treated with primary antibody (no
1° Ab) (Figure 3.3 C) showed no staining. From Figure 3.3B, we observed the fine
astrocyte processes stained with GFAP under fluorescence microscopy.
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Figure 3. 3: GFAP staining for 20,000 cells per mL primary astrocytes. A) Phase
contrast image before staining B) Fluorescence image of GFAP stained astrocytes C)
Fluorescence image of negative controls for GFAP staining of astrocytes Scale bar =
100 µm, Magnification =200X
To simplify quantification of the area covered by each cell type in the co-culture
model, astrocyte cells were stained against GFAP (Figure 3.4) and the nuclei of both
astrocyte and endothelial cells were stained with DAPI for the selected region of interest
(ROIs) for superior visualization of both cell types in the system. Figure 3.4 shows two
such ROIs selected for quantification stained with GFAP (green) and DAPI (Figure 3.4
A-C) and stained with GFAP (red) and DAPI (Figure 3.4 D-F).
The GFAP stained pictures of co-culture were then analyzed under image pro 7
software for analysis of the area covered by astrocytes in the co-culture model.
3.3.3

Area Analysis
Figure 3.5 shows the area covered by GFAP staining, which approximated the

astrocyte area coverage in the co-culture model. The result indicates that astrocytes
occupied a mean area of 300786±21800 pixel2 in an ROI with a total area of 1383455
pixel2 as shown in Figure 3.5A, which accounts for 25±1.57 % of area coverage by
astrocytes in the co-culture model (Figure 3.5B). As the cell growth was terminated
when the cells reached close to 80% confluency, the approximate area of endothelial cell
coverage was estimated by subtracting the area covered by astrocytes from the total area
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covered by cells per ROI and found to be at 54.4% (Figure 3.5B). Therefore, the coculture model consists of approximately twice as many BMVECs as the astrocytes.

Figure 3. 4: GFAP staining for 20,000 cells per mL co-culture model showing brain
astrocytes stained against GFAP amongst endothelial cells’ nuclei stained with DAPI.
Top panel presents images for co-culture model stained against GFAP- Green and
bottom panel shows images for model stained against GFAP- Red. (A-D) Astrocytes
in the co-culture model stained against GFAP, (B-E) DAPI image for regions shown
in (A-D) and (C-F) Merged images for region for (A-B) and (D-E) showing astrocytes
stained with GFAP amongst the nuclei of endothelial cells. Scale bar = 100 µm.

Figure 3. 5: A) Mean area coverage by astrocytes per ROI B) Percentage of area
covered by astrocytes and BMVECs; in the Co-culture model plated with 1:1 ratio
of Astrocytes and BMVECs for 2 experiments (N=2) with four wells (n=4) each
experiment. Error bar represents SEM values and “**” represents p<0.01.
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3.4

Conclusion and Discussion

A co-culture model of BMVECs and astrocyte plated at the ratio of 1:1 was developed in
vitro and characterized through GFAP staining against astrocytes. The area covered by
astrocytes on the co-culture model was quantified by GFAP image analysis, which was
used to approximate the area coverage of BMVECs by subtracting the area covered by
GFAP to the total area of image, considering the cells were ~80 confluent. The results
showed that the co-culture model consists of nearly two-fold of BMVECs compared to
astrocytes, which is reasonable, given that astrocytes exhibit slower proliferation than
endothelial cells (149) and that they require nearly twice as much time to reach the
confluency, as was observed for BMVECs cultured under same condition in the
experiments. Different ratios of astrocytes and endothelial cells could be selected for the
co-culture model to understand the influence of one cell type on other, however it can be
complicated to control and estimate the cell growth in vitro cultures when uneven ratios
of cells are selected.
The co-culture model was developed to investigate the role of astrocytes in
influencing the activity of endothelial cells, therefore, a model with lesser number of
astrocytes compared to endothelial cells provides better validation of influence as it
prevents the system to be dominated by astrocytes activity. The co-culture system
developed in this study is simply reproducible and better mimics cell-cell interactions
than the monocultures. It is therefore an optimized model to study how the presence of
astrocyte modulates the BMVECs behavior because it includes cellular interaction
between a particular population of astrocyte and endothelial cells.

ASTROCYTES PROVIDE NEGATIVE FEEDBACK TO
NITRIC OXIDE SYNTHEIS FROM BRAIN
MICROVASCULAR ENDOTHELIAL CELLS DURING
INFLAMMATION

4.1

Introduction

NO is a vasoactive signaling molecule expressed in both normal and disease states
in the brain. It generally helps the body to maintain blood pressure at normal levels, but
this tiny gaseous molecule can be damaging, acting like a prooxidant when recruited by
the immune system. During neuroinflammation, NO often causes the most damage to key
glial cells. Activation of microglia, astrocytes, and endothelial cells during inflammation
results in successive release of cytokines, chemokines, cell adhesion molecules and
expression of surface antigens which enhance immune cascade in CNS, resulting in
increased immune cell infiltration into the CNS if left unchecked (150,151).
Inflammatory reactions are an important contributor to neuronal damage in a wide variety
of neurodegenerative disorders like PD, AD, and MS, ALS, and some forms of epileptic
seizures(6). Failure of the BBB has been associated with inflammatory processes and is
widely being investigated as a key area for drug delivery to treat neuronal and mental
diseases (152,153). During inflammation, excessive NO synthesis can form the reactive
nitrogen species, ONOO-, which is a toxic molecule that can cause initiation of the
neurodegenerative process and cause neuronal death. NO signaling has been suggested to
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promote BBB permeability while its specific role in NO-related tissue injury and BBB
opening is not yet clear (92). NO synthesis and modulation in BBB cells during
inflammation, its effect on cellular networks, and the subsequent changes in Ca ++
dynamics will provide a better insight to analyze NO-induced neurodegeneration and
BBB permeability.
4.2
4.2.1

Materials and Methods

Cell Culture
Primary BMVECs were plated at the density of 10,000 cells (10k) per mL in a 48

well cell culture plate. The cells were grown in the Rat Endothelial Growth Media (Cell
Application Inc.) (Appendix C.3), which constitutes rat endothelial growth factor
(6%v/v) and penicillin/streptomycin (0.5% v/v) and incubated at 5% CO 2 and 37 °C until
they reached ~30% confluency.
Primary Astrocytes were seeded at densities of 20,000 cells per mL in a 48-well
cell culture plate, grown in astrocyte media (Appendix C.4) with F-12 Ham media plus
L-glutamine and sodium bicarbonate (Sigma-Aldrich) with horse serum (5% v/v), fetal
bovine serum (5% v/v), and penicillin/streptomycin (0.5% v/v), and incubated at 5% CO 2
and 37 °C in a humidified incubator until they reached ~30% confluency. BMVECs
exhibits a higher proliferation rate than the astrocytes. Therefore, 10k and 20k cell
densities of BMVECs and astrocytes respectively were selected to maintain confluency
for both cell types at the approximately same level over time.
For a co-culture experimental model, BMVECs and astrocytes were seeded at the
ratio of 1:1 into the same well in their respective growth media with direct cell-cell
contact in a 48-well cell culture plate (Greiner) and allowed to grow at the same
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condition as the monocultures until they reach ~30% confluency. Each culture was
treated with an inflammatory stimulus after they reached ~30% confluency.
4.2.2

Treatment with Inflammatory Stimulus

A combination of inflammatory agents, 100 ng/ml of Tumor Necrotic Factor (TNF)
(Sigma Aldrich), and 5 µg/ml of Lipopolysaccharide (LPS) (Sigma Aldrich) were used to
treat the cells. The cells were then incubated at 37 °C and 5% CO2 until 6 DIV (days in
vitro). NO assay was performed to indirectly determine the concentration of NO by
quantifying the concentration of NO2- , the stable decomposition products of NO. NO2accumulated in each well on 2, 4, and 6 DIV for both cell types and their co-culture
model was quantified using spectrophotometry. After each NO assessment, the cells
were fed with 100 µl of their respective fresh media to compromise for the volume taken
for the assay.
4.2.3

NO Assay
For quantitative colorimetric determination of NO, Invitrogen™ Griess Reagent

Kit (#LSG-7921) for nitrite quantification was obtained from Thermo Fisher Scientific
and used according to standard protocols (Appendix I). 100 µL of the sample
(media from cells treated and non-treated with inflammatory stimulus) was transferred to
a 1.5 ml Eppendorf tube constituting 866.5 µL of water on top of which 16.5 µL each of
working reagent A and reagent B were added. Standard curves of 5,25 and 50 µM were
prepared as well. The mixtures were vortexed to mix the sample and reagent thoroughly
and incubated in dark at room temperature for 30 minutes. Spectrophotometric
measurements were carried out using Beckman Coulter DU 800. Absorbance readings for
each sample were obtained at 548 nm. The standard curve equation (0.98≤R≤1) was used
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to convert the absorbance readings to corresponding NO concentrations values in MS
Excel.
4.2.4

Lumen Quantification
Digital microscopy images of the BMVECs’ cellular networks were taken at 6

DIV after treatment and before cell fixation for DAPI staining. Three pictures of each
well were taken by selecting random ROIs for 4 wells (n=4) per condition for 3 different
experiments (N=3). The empty spaces surrounded by cells (lumens) were quantified for
their count and area coverage using Image Pro 7 software as shown in Appendix A.2 and
Figure A.2.
4.2.5

DAPI Analysis
The cells were fixed after NO assay on 6 DIV. The nuclei of fixed cells were

stained with DAPI (4′,6-diamidino-2-phenylindole) (Appendix G.1) to analyze and
compare the cell proliferation rate and nuclear area factor (NAF) (154) in between the
cells treated and non-treated with the inflammatory stimulus. DAPI images for both
treated and non-treated conditions were taken by selecting 3 random ROIs within the
fluorescence microscopy field. The total count of nuclei and NAF (roundness x size)
where roundness is defined in the Image Pro 7 as (perimeter2)/ (4 x pi x area) were
calculated for each ROI and averaged over each condition for 3 different experiments
using Image Pro 7 software.
4.2.6

Microscopy
Microscopic images of the cells were recorded using a Leica DMI 6000B

microscope. For quantification of the lumen, phase-contrast microscopy was used, while
for DAPI Analysis, fluorescence microscopy was used. For fluorescence microscopy, a
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Leica EL6000 light source was used with an excitation light in the ultraviolet range (~400
nm) to view DAPI-stained nuclei.
4.2.7

Image Analysis
Image-Pro Plus version 7.0 developed by Media Cybernetics was used to perform

all image analysis. The total number of lumens and area covered by the lumens in
BMVECs were determined by analyzing the phase microscopic pictures of selected ROIs
(Appendix B). For images stained with DAPI, the total number of nuclei and their NAF
were calculated.
4.2.8

Statistics
Statistical analysis was performed as described in Section 3.2.8.
4.3

4.3.1

Results

NO Assay
NO Assay was performed on 2,4 and 6 DIV after treatment with inflammatory

stimulus for the mono-cultures of BMVECs and astrocytes as well as their co-culture
model. A non-linear increase in NO synthesis was seen in BMVECs treated with
inflammatory stimulus compared to the control cells with 3.5±0.5 µM mean increase in
NO2 concentration on day 2 that increased significantly to 10.5±0.7µM and 26±0.3 µM
by day 4 and day 6 after treatment, respectively. An opposite trend of NO synthesis was
seen in astrocytes with NO2 concentration decreasing from day 2 to day 6 after treatment.
Astrocytes treated with inflammatory stimulus showed a mean increase in NO 2 at
2.5±0.3µM on day 2 compared to the control cells which went down slightly to 2.3±1.4
µM and 1.2 ± 0.3 µM by day 4 and day 6, respectively. NO synthesis in astrocytes
saturated by day 4, resulting in concentrations either close to day 2 or significant
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decrease, as observed for day 6. The co-culture model shows a salient feature close to
BMVECs culture with the trend of NO2 concentration in stimulated cells going up from
day 2 to day 6 after treatment markedly at a reduced level. Mean NO 2 increase was seen
at 1.2±0.1 µM on day 2, 2.2±0.1µM on day 4, and 3±0.3µM on day 6 for the inflamed
cells compared to the controls.

Figure 4.1: Concentration of NO2 released by BMVECs, astrocytes and their coculture model for 2,4 and 6 DIV after preincubation with the inflammatory stimulus
(100 ng/ml of TNF+ 5ug/ml of LPS) 37 °C. Data represent an average of three
experiments (N=3) with triplicated wells (n=3), where ‘***’ represents p<0.001 and
‘**’ represents p<0.01. Error bars represent SEM values.
BMVECs were also tested for NO synthesis with an individual stimulus of 100
ng/ml of TNF alone and 5 µg/ml of LPS alone to test the efficiency of the combination of
the stimulus used for the experiment. No significant production of NO was found in cells
treated with only one of these stimuli, with the amount of NO 2 formed at a level close to
the control cells. A widely used NO inhibitor, L-NAME (N(ω)-nitro-L-arginine methyl
ester) was introduced to both control and stimulated BMVECs which suppressed the NO
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release in all conditions thus validating the measured release and inhibition profiles of
NO in the cells as mediated by NOS enzyme (Appendix A.1).
4.3.2

Lumen Quantification and Cell Metabolism
After treatment with the inflammatory stimulus, the BMVECs cells were imaged

at 3 and 6 DIV to observe morphological changes in the cellular network. The stimulated
cells showed the formation of lumens (115) in vitro while controls showed no sign or
minimal sign of lumen formation. Higher metabolism was observed in the stimulated
cells that showed this change in morphology indicated by a change in pH which is
represented by the change in color (yellowish) compared to control (reddish) as shown in
Figure 4.2.

Figure 4. 2: Microscopic images for 10k per mL of BMVECs taken after
preincubation with the inflammatory stimulus at 37°C at 3 DIV A) Control cells (B)
Treated Cells and at 6 DIV C) Controls D) Treated cells. Scale bar = 100µm,
Magnification =100X.
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The quantification of lumen formation between cellular networks by 6 DIV after
treatment with inflammatory stimulus showed elevated numbers of lumens in the treated
wells compared to the controls, which showed only a few or no lumen formation. Image
pro 7 software was used to quantify the number and area of lumens, as shown in
Appendix A.2. A mean of 32±1 lumen per ROI was found for the stimulated cells while
control cells showed a mean of 2±1 lumens per ROI (Figure 4.3A). The total area
covered by the lumens per ROI was 230,831 ±469 square pixels for the stimulated cells
and for control it was 15,534±110 square pixels (Figure 4.3B).

Figure 4. 3: Graphs showing the difference between BMVECs stimulated with
inflammatory stimulus and controls in A) the number of lumens B) total area covered
by the lumens - per ROI on 6 DIV. Data represent an average of three experiments
(N=3) with triplicated wells (n=3), where ‘***’ represents p<0.001. Error bars
represent SEM values.
4.3.3

DAPI Analysis

Cell proliferation and cellular size of BMVECs and astrocyte cells were compared,
analyzing the total number of nuclei and the nuclear area factor per region of interest
(ROI) calculated by analyzing the DAPI images as shown in Figure 4.4 of the stimulated
and control wells using Image Pro 7 software.
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For BMVECs plated at 5k and 10k per mL, the cells treated with inflammatory
stimulus showed a nuclei count of 598 ±15 and 594±13, respectively (Figure 4.5), which
is significantly higher than the control cells. Control cells showed a nuclei count of 249
±17 and 330±24. NAF is used to determine the difference between the nuclei size and to
give us information corresponding to cell size or shrinkage caused by contact inhibition or
apoptosis. As shown in Figure 4.6, for cells plated at 5k and 10k per mL, stimulated cells
showed comparatively smaller NAF than control. Control cells plated at 5k and 10k
densities showed a NAF of 1248±111 and 1101±101 square pixel, respectively, while the
cells treated with inflammatory stimulus showed an NAF of 825±89 and 796±75 square
pixel, respectively.

Figure 4. 4: DAPI images taken at 6 DIV after preincubation with the inflammatory
stimulus at 37 °C for 10k per mL of BMVECs (A) Control cells (B) Treated cells and
20k per mL of astrocytes (C) Controls (D) Treated cells. Magnification = 200X.
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Figure 4. 5: Total number of nuclei per ROI controls and stimulated BMVECs plated
at 5k and 10k per mL after preincubation with inflammatory stimulus for 6 DIV at 37
°C. Data represent an average of three experiments (N=3) with triplicated samples
(n=3) each, where ‘**’ represents p<0.01, and ‘*’ represents p < 0.05. Error bars
represent SEM values.

Figure 4. 6: NAF per ROI for controls and stimulated BMVECs plated at 5k and
10k per mL after preincubation with inflammatory stimulus for 6 DIV at 37 °C.
Data represent an average of three experiments (N=3) with triplicated samples
(n=3) each, where ‘***’ represents p<0.001 and ‘*’ represents p < 0.05. Error bars
represent SEM values.
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Figure 4. 7: Total number of nuclei per ROI for controls and stimulated astrocytes
plated at 10k and 20k per mL after preincubation with inflammatory stimulus for 6
DIV at 37°C. Data represent an average of three experiments (N=3) with triplicated
samples (n=3) each, where ‘***’ represents p<0.001 and ‘*’ represents p < 0.05,
averaged over 3 experiments(N=3) with 3 samples per condition (n=3). Error bars
represent SEM values.

Figure 4. 8: Nuclear Area Factor per ROI for controls and stimulated astrocytes
plated at 10k and 20k per mL, after preincubation with inflammatory stimulus for
6 DIV at 37 °C, where ‘***’ represents p<0.001 and ‘*’ represents p < 0.05,
averaged over 3 experiments (N=3) with 3 samples per condition(n=3). Error bars
represent SEM values.

56
Figure 4.7 shows that the astrocytes plated at 10k and 20k per mL showed a nuclei
count of 443±9 and 552±20, respectively, for the stimulated cells. These counts are
significantly higher than the control cell counts, which were 164 ±6 and 244±10. NAF was
found to be 812±16 and 734±6-pixel square control cells which is slightly higher than
688±13 and 563±9-pixel square of NAF shown by the stimulated cells plated at 10k and
20k per mL respectively (Figure 4.8). Significantly higher nuclei count and smaller sized
nuclei in both the BMVECs and astrocyte culture indicate higher cellular proliferation in
the cells stimulated with inflammatory stimulus.
4.4

Conclusion and Discussion

BMVECs monocultures produced significantly high amount of NO over time
when induced with inflammatory stimulus. The presence of astrocytes in the co-culture
model significantly inhibited the NO production from BMVECs for the same amount of
stimulation. This suggests that astrocytes provide negative feedback to the positive
feedback mechanism of NO synthesis in BMVECs during inflammation, preventing the
potential neurological pathology due to availability of excess NO in the brain such as the
toxicity due to ONOO- formation.
The analysis of morphological changes over time for BMVECs and astrocyte
culture showed higher cellular proliferation in both cultures when stimulated with
inflammatory factors, as verified by DAPI image analysis for cell count and NAF.
BMVEC cultures treated with inflammatory stimulus also showed higher cell
metabolism, indicated by pH change of media and formation of a significantly larger
number of irregular lumens or holes in between cellular networks. While the proliferating
endothelial cells also organize into tubular structures in normal BMVECs cultures, which
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is the indication of vascular morphogenesis, the fully grown culture showed a compact
cellular monolayer with negligible lumen formation. In contrast, the BMVECs cultures
induced with inflammation showed changes in cell morphology with increased number of
lumens formed by stretched out cells networking with each other, which might be due to
TNF induced shift in cytoskeletal dynamics, as suggested by Stroka et al. (155). The
increased lumen numbers have often been associated to inflammation induced
angiogenesis in the literature, however, the lumens persisted even after the cell growth
was suppressed by contact inhibition in contrast to normal endothelial culture grown in
media with angiogenic factors. TNF and LPS have also been suggested to degrade
glycocalyx (156) and disrupt and downregulate TJ protein (157–159), and therefore these
increased number of irregular lumens between cellular networks, might be an indication
of inflammation related blood brain barrier disruption in vitro.

COPPER HIGH ASPECT RATIO STRUCTURES CAN
CATALYZE THE RELEASE OF NITRIC OXIDE FROM
NORMAL BMVECS

5.1

Introduction

NO is a bioactive signaling molecule essential for a wide variety of physiological
conditions such as cardiovascular homeostasis, inflammatory responses,
immunomodulation, tumor growth, ion channel modulation, and reproduction (160).
These diverse roles of NO have paved a path for huge research interest in therapeutics
related to exogenous NO delivery or NO catalysis in vivo for biomedical applications
(161). In the brain, it has an important role mainly in neuronal signaling and
neurovascular coupling (NVC)(80,162). The brain microvascular endothelial cells
(BMVECs) are a major part of the neurovascular unit (163). NO released from these cells
relaxes the vascular smooth muscle cells and controls blood flow to the brain, thus
playing a central role in NVC. In this chapter we investigated the role of a copper-cystine
biohybrid known as Copper High Aspect Ratio Structures (CuHARS) in catalyzing the
NO production from normal BMVECs, underlining the neuroprotective roles of
endothelial NO (164–167). As NO donors have been known to modulate oxidative stress
and inflammation (168), here we attempt to find a therapeutic application of CuHARS for
brain disorders involving disruption of NVC, oxidative stress, and inflammation such as
ischemic stroke, neurodegenerative diseases, and brain injuries. Since it is well
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established from the previous chapter that BMVECs produce an excessive amount of
inducible NO (iNO) during inflammation, in this chapter we also investigated the role of
CuHARS in altering NO release from BMVECs during inflammation by using the
inflammatory stimulus, a combination of TNF and LPS. iNO has a possibly neurotoxic
effect, but also provides flexibility in dealing with immune challenges (169). An
understanding of the effect of CuHARS on inflammatory NO may provide for a new
avenue in mitigating the neurotoxic effect of iNO during inflammation, besides indicating
new wound-healing strategies in other regions of the human body pertaining to
antimicrobial, antithrombotic, and anti-inflammatory properties of NO (170,171).
5.2

Materials and Methods

Chemicals
CuHARS are novel materials that are completely biodegradable and
biocompatible metal-organic biohybrids (MOBs). The CuHARS were discovered and
synthesized in our lab (Cellular Neuroscience Lab) by self-assembly technique and
primarily consists of metallic copper conjugated with L-Cystine. S-nitrosocysteine
(CysNO), a NO precursor normally found in blood freshly prepared at a concentration of
0.1 mM, before each experiment as described by Harding and Reynolds (168). A 0.1mM
solution of Cystine was mixed with 0.1 mMol of tertbutylnitrite in 2 ml of water set up in
an ice bath in a stirrer for 30 mins.
Cell Culture
BMVECs cells were plated at the density of 10k per well in 48 well cell culture
plates and incubated at 5% CO2 and 37 °C. When the confluency of cells reached ~ 60%
the cells were treated with a combination of CysNO and CuHARS. BMVECs were
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treated with 10 and 20 µg/ml of CuHARS in the presence of three different concentration
of CysNO, 10, 25, and 50 µM. The cells were incubated for 4 hours with CuHARS and
CysNO. CRL2303 cell lines were obtained from American Type Culture Collection
(ATCC) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) constituting
fetal bovine serum (5% v/v), amino acid solution (1%v/v), and penicillin/streptomycin
(0.5% v/v), (Appendix C.5) CRL 2303 cells line were used as negative controls to
validate NO catalysis in BMVECs.
5.2.3

CuHARS Treatment in Combination with CysNO
Endothelial cells were plated in 48 well cell culture plates at the density of 10,000

per ml. When the confluency of cells reached ~60%, the cells were treated with 0.1mM of
S-nitrosocysteine (CysNO). Three concentrations of CysNO, 10, 25, and 50 µM, were
chosen to obtain NO release profile using 10 or 20 µg/ml of CuHARS. CuHARS were
added immediately after CysNO to the cells which were then incubated at 37 C and 5%
CO2 for 3 hours. The experiment was replicated with glioma cells for 25 and 50 µM of
CysNO treatment.
5.2.4

CuHARS Treatment in Combination with an Inflammatory Stimulus
The BMVECs plated at 10,000 per ml in 48 well cell culture plates were treated

with an inflammatory stimulus, a combination of 100 ng/ml of TNF and 5 µg/ml of LPS in
the presence and absence of 20 µg/ml of CuHARS when the cells reached ~30%
confluency. The cells were incubated at 37 C and 5% CO2 for up to 96 hours after
treatment to assess the NO release in the cells caused by the inflammatory stimulus. The
NO assay was performed twice on BMVECs at 48 hours and 96 hours after treatment. The
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experiment was replicated in glioma cells to compare NO release at 48 hours after
treatment.
5.2.5

NO Assay

For quantitative colorimetric determination of NO, Invitrogen™ Griess Reagent Kit
(#LSG-7921) for nitrite quantification was obtained from Thermo Fisher Scientific and
used according to standard protocols (Appendix I). A sample of media (100µl) is
collected from the wells after incubation with their respective treatment conditions. The
samples were reacted with Griess Reagent for nitrite (NO 2), a stable breakdown product
of NO) determination as described in the protocol (Invitrogen, G-7921) (Ashpole et al.,
2014). The absorbance values of the solution obtained were read using a
spectrophotometer (Beckman Coulter DU 800) at 548 nm . For each experiment, a
standard curve with four to five standard solutions of nitrite (0, 5, 25, 50, and 75 µM)
obtained from the reagent kit was prepared, which was used to convert the absorbance
values into NO2, concentrations.
5.2.6

MTT Assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a

biochemical assay used to determine the metabolic rate of cells. MTT was obtained from
Thermo Fisher Scientific (Waltham, MA). MTT assay was used as the measure of
cytotoxicity by comparing cellular metabolic activity caused by the presence of CuHARS
and CysNO. It was performed as described by Vives et al. (102). To determine the
cytotoxicity of the treatment, MTT assay was carried out in the presence and absence of 10
and 20 µg/mL of CuHARS in cells treated with 0, 10, 25, and 50 µM of CysNO. A
concentration of 1.25 mg/mL of MTT, a yellow tetrazole, diluted in DMEM without phenol
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red was added to each well after aspirating the media from the cells. The plate was
incubated in a dark environment at 5% CO2 and 37 C for 60 minutes. After incubation,
purple colored formazan crystals formed on the wells were dissolved with 250 µL of 91%
isopropyl alcohol. The resulting solution was transferred into 96 well plate and absorbance
was read at 570 nm, using a 96-well microplate plate reader (Thermo Scientific Multiskan
Spectrum). For CuHARS and CysNO treatment to cells, MTT assay was performed after
24 hours of treatment while for the cells treated with CuHARS and inflammatory stimulus,
it was performed soon after NO assessment at 96 hours for BMVECs and 48 hours for
glioma cells. The cell metabolic activity was analyzed by comparing the absorbance values
of the experimental wells treated with different concentrations of CuHARS and CysNO or
inflammatory stimulus with the absorbance of control wells.
Figure 5.1 represents a schematic that explains the overall experimental layout.

Figure 5. 1: Experimental layout
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5.3

Results

CuHARS Treatment in Combination with CysNO
5.3.1.1

NO Assay
BMVECs with no treatment and those treated with CuHARS alone (controls),

showed no significant increase in NO concentration, while treatment with different
concentration of CysNO (10, 25 and 50 µM) at two concentrations of CuHARS (10 and
20 µg/mL) yielded a concentration-dependent increase in NO release from the BMVECs.
The lower concentration (10 µg/mL) of CuHARS treatment on BMVECs yielded a mean
increase of 1.16±0.41, 4.40±0.15, and 5.62±1.09 µM of NO 2 in presence of 10, 25 and 50
µM of CysNO, respectively (Figure 5.1). This increase in NO2 concentration was greater
with the use of a higher concentration (20 µg/mL) of CuHARS for the same
concentrations of CysNO used. The mean increase in NO2 was found to be 3±0.25, 4.42±
1.21, and 13.98 ± 4.13 µM in presence of 10, 25 and 50 µM of CysNO, respectively
(Figure 5.2). For the conditions with no cells (media only), the NO2 yield was closer to
the cells treated with CysNO alone and less by 2.3±0.27, 6.2±1.48, and 14.6 ±4.15 µM
compared to cells treated with 10, 25 and 50 µM of CysNO and 20 µg/mL of CuHARS
(Figure 5.2).
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Figure 5.1: NO2 concentration in the presence and absence of 10 µg/mL of CuHARS
for treatment of 0,10,25 and 50 µM of CysNO in BMVECs plated at 10k per mL,
after 3 hours of incubation at 37 °C, where ‘***’ p<0.001 and ‘*’ represents p < 0.05,
averaged over 5 experiments (N=5) with 3 samples per condition (n=3). Error bars
represent SEM values.

Figure 5. 2: NO2 concentration in the presence and absence of 20µg/mL of
CuHARS for treatment of 0, 10, 25 and 50 µM of CysNO in wells with cells
(BMVECs) plated at 10k per mL and wells without any cells (media only), after 3
hours of incubation at 37 °C, where ‘***’ p<0.001, ‘**’ represent p<0.01 and‘*’
represents p < 0.05, averaged over 3 experiments (N=3) with 3 samples per
condition (n=3). Error bar represents SEM values.
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Replication of the same experiment in CRL2303 with CuHARS (20 µg/mL) and
CysNO (25 and 50µM) resulted in a slight increase of NO 2 yield of 1.58±0.57 µM and
2.56±0.5 µM, respectively, which is significantly less than the yield observed in
BMVECs (Figure 5.3). No synthesis of NO2 was seen in the CRL2303 cells in the
controls.

Figure 5. 3: NO2 concentration in the presence and absence of 20 µg/mL of CuHARS
for treatment of 0, 25 and 50 µM of CysNO in wells with CRL2303 cell line plated at
10k per mL after 3 hours of incubation at 37 °C, where ‘***’ represent p<0.001,
averaged over 3 experiments (N=3) with 3 samples per condition (n=3). Error bar
represents SEM values.
5.3.1.2

MTT Assay

MTT assay of CuHARS treatment on BMVECs in the presence of CysNO showed no
toxicity to the cells but indicated higher cell metabolism between 10 to 20% by 24 hours
of treatment. At a lower concentration of CuHARS (10 µg/mL), cell metabolism
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increased by a mean of 2 to 17% for different concentrations of CysNO used (Figure
5.4). The cell metabolism increased by a mean of 10% for the control cells and by 25% at
10 µM, 15% at 25 µM, and 3% at 50 µM CysNO for cells treated with 20 µg/mL of
CuHARS compared to the cells treated with CysNO alone (Figure 5.6). The toxicity of
CuHARS on the BMVECs cells without any treatment was also assessed using the Diff
Quik staining technique for 24 hours treatment on the cells and compared with CuNPs
that act as positive controls for toxicity in cells. CuHARS were found to be significantly
less toxic compared to CuNPs at the same concentration of 6 µg/ml (Figure A.3 -A.4,
Appendix A).

Figure 5. 4: Cell metabolism as a measure of cell viability for 10k BMVECs after
incubation with 0, 10, 25 and 50 µM of CysNO in the presence and absence of 10
µg/mL of CuHARS, after 24 hours of incubation at 37 °C, where ‘***’ p<0.001 and
‘*’ represents p < 0.05, averaged over 3 experiments (N=3) with 3 samples per
condition (n=3). Error bar represents SEM values.
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Figure 5. 5: BMVECs plated at 10k per mL (A) Controls (B) Cells treated with 10
µg/mL of CuHARS at 24 hours after treatment showing no toxicity to the cells,
Magnification 200X, Scale=100 µm.

Figure 5. 6: Viability of 10k BMVECs after incubation with 0, 10, 25 and 50
µM of CysNO in the presence and absence of 20 µg/mL of CuHARS, after 24
hours of incubation at 37 °C, where ‘***’ represents p<0.001 and ‘*’
represents p < 0.05, averaged over 3 experiments (N=3) with 3 samples per
condition (n=3). Error bar represents SEM values.
MTT assay at 24 hours after treatment in glioma cells for the same treatment
conditions showed a 10% decrease in cell metabolism for the control cells treated with
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CuHARS alone (20 µg/ml) compared to non-treated cells. The cells treated with 25 and
50 µM CysNO alone showed a slight increase in cell metabolism at lower concentrations
(25 µM) which decreased slightly with higher concentrations used. This increase in cell
metabolism by CysNO was reversed by the presence of 20 µg/ml CuHARS which
inhibited the metabolism by 13 and 7% for cells treated with 25 and 50 µM CysNO,
respectively (Figure 5.7). As CuHARS is a slowly degrading material, the viability for
glioma cells continues to decrease with increasing time in response to the toxicity
imparted by the release of copper from CuHARS, as shown in Karekar et al. (169) and
further demonstrated by the following sections of this research.

Figure 5. 7: Cell metabolism as a measure of cell viability for 10k glioma cells
(CRL2303) after incubation with 25 and 50 µM of CysNO in the presence and
absence of 20 µg/mL of CuHARS after 24 hours of incubation at 37 °C, where ‘***’
p<0.001, ‘**’ represents p < 0.01 and ‘*’ represents p < 0.05, averaged over 3
experiments (N=3) with 3 samples per condition (n=3). Error bars represent SEM
values.
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CuHARS Treatment in Combination with an Inflammatory Stimulus
5.3.2.1

NO Assay
NO concentration was measured on the BMVECs with the inflammatory stimuli

(100 ng/ml TNF+5 µg/ml LPS) in the presence and absence of 20 µg/ml of CuHARS.
The concentration of NO increased significantly for BMVECs supplied with
inflammatory agents compared to the controls, but strikingly, the presence of CuHARS
inhibited the NO release from these stimulated cells in contrast to the results observed for
normal cells when the NO donor, CysNO is supplied as discussed in Section 5.3.1. NO2
absorbance readings were taken at 48 hours and 96 hours. At 48 hours, an increase in
4.9±0.5 µM of NO2 was observed in BMVECs stimulated by inflammatory agents alone
compared to the control cells which were inhibited by 1.8±0.6 µM due to the presence of
20 µg/ml CuHARS and by 96 hours these values went up to 9.6±0.5µM increase and
3.1±0.7µM inhibition respectively (Figure 7A). Treatment of wells with L-NAME
resulted in significant inhibition of NO release in all conditions thus validating the
measured release and inhibition profiles of NO in the cells as mediated by NOS enzyme.
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Figure 5. 8: NO2 concentration in the BMVECs due to the treatment of inflammatory
stimulus in the presence and absence of 20µg/ml of CuHARS and negative controls
treated with LNAME, a NOS inhibitor. Data represent an average of three
experiments(N=3) with triplicated wells (n=3). The error bars represent SEM
values,“***” represents p<0.001, “**” represents p<0.01, and “*” represents p<0.05.
In contrast to results observed for BMVECs, a two-fold increase in NO 2 synthesis
(2.2 µM) was observed in glioma cells treated with the inflammatory stimulus in the
presence of 20 µg/ml of CuHARS compared to the cells treated with the inflammatory
stimulus alone (1.1 µM), 48 hours after the treatment (Figure 5.9). Treatment with
inflammatory stimulus resulted in a modest increase of 0.5±0.2 µM of NO 2 while the
combinatory treatment of the stimulus and CuHARS led to an increase of 1.6±0.2 µM
compared to the non-treated control cells. The addition of (N(ω)-nitro-L-arginine methyl
ester (LNAME), a NOS inhibitor to the system, resulted in significant inhibition of the
NO produced in the wells, thus validating the conclusion that NO increase was caused by
CuHARS, as measured via the enzyme NOS.
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Figure 5. 9: NO2 concentration in the BMVECs due to the treatment of inflammatory
stimulus in the presence and absence of 20µg/ml of CuHARS and negative controls
treated with LNAME, a NOS inhibitor. Data represent an average of three
experiments(N=3) with triplicated wells (n=3). The error bars represent SEM
values,“***” represents p<0.001, and “*” represents p<0.05.
5.3.2.2

MTT Assay
MTT results for BMVECs treated with inflammatory stimulus showed a more

than 2 fold increase in cell metabolism compared to the controls at 96 hours time point.
The cells treated with the combination of inflammatory stimulus and CuHARS showed
slight inhibition in metabolism compared to those treated with inflammatory stimulus
alone, but a significant increase in metabolism compared to the controls with no
treatment and treated with CuHARS alone. No significant inhibition was observed in the
presence of CuHARs on normal BMVECs and the metabolism was reduced by 12% for
stimulated cells and 14% for the LNAME treated cells showing the inhibitory potential of
CuHARS on higher cellular proliferation of BMVECs after the inflammatory stimulus
(Figure 5.10).
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Figure 5. 10: Graph showing cell viability in 10K BMVECs after the treatment,
indicating a significant increase in cell metabolism in BMVECs treated with
inflammatory stimulus alone, compared to the controls and slight inhibition due to
CuHARS in the cells treated with the combination of CuHARS and inflammatory
stimulus. Data represent an average of three experiments(N=3) with triplicated wells
(n=3). The error bars represent SEM values,“***” represents p<0.001, “**” represents
p<0.01, and “*” represents p<0.05.
Morphological evaluation of cells treated with the inflammatory stimulus or with
inflammatory stimulus plus CuHARS in glioma cells supported metabolic biochemical
assays (Figure 5.11 and Figure 5.12). CuHARS could be observed under inverted phase
microscopy in cultures treated with 20 µg/ml of the materials (Figure 5.11C), and when
combined with inflammatory stimulus, this diminished cell number compared to control
wells (Figure 5.11A).
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Figure 5. 11: Glioma cells treated with the inflammatory stimulus in presence of
20µg/ml of CuHARS causes significant toxicity to the cells. A) Control cells treated
with media alone B) Cells treated with inflammatory agents C) Cells treated with
inflammatory agents and 20µg/ml of CuHARS, Scale bar=100µm;
Magnification=200X.
An MTT assay was performed after 48 hours of treatment to quantify cellular
metabolism of glioma cells with no treatment (controls) and with the treatment of
inflammatory stimulus in the presence or absence of 20 µg/ml of CuHARS to determine
the cytotoxicity of the treatment. The assay indicated no significant difference in cell
metabolism for glioma cells treated with inflammatory agents computed by comparison
to the control conditions. In contrast, the metabolism of cells treated with CuHARS
decreased in all conditions treated with CuHARS with a significant decrease of 25% by
48 hours in line with the 10% decrease observed within 24 hours for controls (Figure
5.7). The cytotoxicity of the treatment was explicitly visible under the microscope as
shown by images captured from the Leica DMI 6000B microscope (Figure 5.11). For the
cells treated with inflammatory agents in the presence of CuHARS, metabolism
decreased by 15% only, which can be compared to increased metabolic activity after
treatment with inflammatory agents in other cell types (170,171). Suppression of NO
release on cells treated with L-NAME led to decreased cell metabolism by 10%, which
was further suppressed by another 10% (overall 20%) after the use of CuHARS (Figure
5.12).
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Figure 5. 12: Cell viability as measured by the MTT assay. No increase in cell
viability was seen in glioma cells treated with inflammatory stimulus alone, compared
to the controls, and significant inhibition was seen after treatment with CuHARS in
the control cells and in cells treated with the combination of CuHARS and
inflammatory stimulus. Data represent an average of three experiments(N=3) with
triplicated wells (n=3). The error bars represent SEM values,“***” represents
p<0.001, and “*” represents p<0.05.

5.4

Conclusions

CuHARS can catalyze NO production in BMVECS when interacted with CysNO,
an NO precursor normally found in the blood thus significantly increasing NO
availability in blood and posing a therapeutic potential for brain conditions related to NO
and NVC disorder. The NO concentration thus formed depends on the availability of both
CuHARS and CysNO, as shown by the increase in NO release with increasing
concentration of CysNO and CuHARS used. The reaction is limited only by the
availability of CysNO as it is a transient molecule which degrades quickly (within few
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hours) while CuHARS are known to last longer (days) depending on the cell types. The
significant inhibition of NO with the use of LNAME validates the NO increase after
CuHARS treatment, as measured via the enzyme NOS. The glioma cell line (CRL2303)
is used as a negative control for NO synthesis, and the positive control for cytotoxicity
shows significantly less NO release and an explicit toxic response compared to
BMVECs, thus further supporting the role of CuHARS as a NO catalyst in BMVECs,
This role is potentially neuroprotective and may be useful for treatment of abnormalities
of NVC disorders. CuHARS's role in inhibiting inducible NO (iNO) during
inflammation, which has neurotoxic roles, further reinforces its potential neuroprotective
property. The ability to target and inhibit glioma cell lines without affecting the cellular
metabolism of the structural cell BMVECs while increasing the production of NO, a key
contributor of an immune response in glioma (165,172), stretches the scope of CuHARS
for therapeutic applications in targeting brain cancer cells.

ASTROCYTES MODULATE THE CALCIUM
DYSREGULATION IN THE BMVECS DURING
INFLAMMATION

6.1

Introduction

Calcium is the second messenger of diversified signaling pathways such as energy
production, synaptogenesis, synaptic transmission, neuronal gene expression, cell
survival, and processes central to learning and memory. It therefore plays a fundamental
role in neuronal plasticity (118). Endothelial cells control the vascular tone in a Ca ++
dependent manner, but most of the research related to NVC has been biased towards the
role of neurons and astrocytes in triggering NVC (119). Intracellular calcium
concentration ([Ca++] i) is a key controller of BBB permeability with an increase in Ca ++
interfering with tight junction development (120). Ca ++ overloading and excessive NO
production along with other events like radical formation have been an area of interest as
they contribute altogether to a wide variety of brain damage (113).
In Chapter 4, an excessive increase in NO was found over time in BMVECs
during inflammation, where astrocyte can provide negative feedback to this NO, thus
inhibiting the NO production from BMVECs in the coculture model. Our specific
objective in this chapter is to test the role of NO in calcium activity of the BMVECs and
astrocytes. A widely used NO donor sodium nitrite (NaNO2)(173–175) will be applied,
in the presence and absence of d-serine, a gliotransmitter and an NMDA co-agonist
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(176). Results are expected to show that endothelial NMDA has a role in NO-dependent
calcium activity, as suggested earlier by Lemaitre et al. (177). Further, we will analyze
the effect in calcium activity after inflammatory stimulation, which represents a cascade
of chemical signaling, not merely the alteration of NO, in the BMVECs and astrocyte
cultures. We will test how the cellular interaction between the two cell types alters the
Ca++ activity in the co-culture model during inflammation.
6.2
6.2.1

Materials and Methods

Chemicals
Calcium indicator dye, Fluo-3 AM was obtained from Invitrogen. Locke’s

solution was prepared in the lab following Locke’s protocol (Appendix C.6). Agonists
adenosine triphosphate (ATP), glutamic acid (Glu), and d-serine were bought in powder
form (Sigma). Ionomycin (Iono) is the calcium ionophore that facilitates the movement
of calcium in and out of the cells, is used as a positive control for calcium influx in the
cells.
6.2.2

Cell Culture
Primary BMVECs and astrocytes were seeded at the density of 10,000 (10k) and

20000 (20k) per mL respectively, as mentioned Section 4.2.1. The cells were grown until
they reached ~70% confluency for experiments designed to study the effect of NO donor
in calcium activity of cells, while the cells for experiments designed to study
inflammation-related calcium changes were treated with inflammatory stimulus when
they reach ~30% confluency. The co-culture model was also grown at the same condition
as the monocultures until they reach ~30% confluency.
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6.2.3

Calcium Activity in BMVECs and Astrocytes with NO Donors
Since an excessive increase in NO over-time was found in response to

inflammatory stimulus in BMVECs, our objective here is to see how NO affects the
calcium activity in BMVECs and astrocyte cells. BMVECs were treated with an NO
donor, sodium nitrite (NaNO2) in the presence and absence of d-serine, an NMDA coagonist which has been suggested to help in vasodilation in the eNOS-dependent
mechanism when used in combination with glutamate (173).
6.2.3.1

Calcium Imaging after Treatment with NO Donor
Calcium imaging was performed on BMVECs and astrocytes after they reached

the confluency ~75%. First, the cells were loaded with 500 µl of Fluo-3 loading solution.
The loading solution constitutes warm Locke’s solution with Fluo-3 dye (1:500) and
Pluronic acid (1:1000). The cells were treated with this solution for 1 hour at 37 °C, in a
5% CO2 incubator. After an hour of incubation, the loading solution on the cells was
pipetted out and the cells were treated with 500 µl of recovery solution which constitutes
Locke’s solution warmed at 37 0C. The cells were incubated in the recording solution for
45 mins at 37 0C, in 5% CO2. During the loading and the recovery phase, the
experimental wells were treated with 5 µM of (NaNO2) in the presence and absence of
100 µM of D-serine (DS), both diluted in Locke’s solution, making a total incubation
time of 1 hr and 45 mins. The control wells were treated with Locke’s alone. The cells
were imaged after the recovery period while being stimulated with three different
agonists, ATP 100 µM, Glutamate 100 µM, and Ionomycin 1 µM to induce calcium
signaling. Fluorescent intensity changes in the cells in real-time, which corresponds to the
calcium influx caused by stimulation via agonist, was imaged and recorded in real-time
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under the inverted microscope (Olympus CKX41) with a 488 nm excitation wavelength
filter at a frame rate of 4 seconds. The experiment was visualized and recorded in the
Intracellular Imaging software (InCyt Im™ Imaging system, version 5.29e, Cincinnati,
OH). Figure 6.1 presents the schematics for recording calcium signals from BMVECs
after pre-treatment with NO donor when stimulated by ATP, glutamate and ionomycin.

Figure 6. 1: Experimental layout for calcium imaging in BMVECs and astrocyte cells
for treatment with NO donors in the presence and absence of D-serine.
6.2.3.2

Measuring and Analyzing Calcium Fluorescence Intensity

The recorded experiments were analyzed in InCyt Im™ Imaging System software.
Regions of interest (ROIs) were created as a circle around each cell constituted in a
frame. ROIs were selected in the frame with maximum fluorescence in response to ATP
stimulation to maximize the visualization and analysis of the number of cells in the
frame. The ROIs were then used to measure the fluorescence intensity of each cell over
time. The data obtained for fluorescence intensity over time for each ROI were then
normalized to their starting values (baseline) in Microsoft Excel, for obtaining correlation
between cells within an experiment and with other experiments. The normalized values
of fluorescence intensity over time are represented on line graphs. The averages of peak
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fluorescence intensity, number of oscillations, decay time, and number of cells
responding or not responding to a stimulus, were calculated depending on the experiment,
and the values were averaged over 3 experiments.
6.2.4

Calcium Activity in BMVECs, Astrocytes and Co-culture Model using

Inflammatory Stimulus
After finding out the response of NO donors in the BMVECs and astrocytes, a
calcium activity study was performed on BMVECs, astrocytes, and co-culture models
using inflammatory stimulus.
6.2.4.1

Treatment with Inflammatory Stimulus

A combination of inflammatory agents, 100 ng/ml of Tumor Necrotic Factor (TNF)
(Sigma Aldrich), and 5 µg/ml of Lipopolysaccharide (LPS) (Sigma Aldrich) were used to
treat the cells when they reach ~30% confluency. The cells were incubated at 37 °C and
5% CO2 until 4 DIV after treatment.
6.2.4.2

Calcium Imaging
Calcium imaging was performed on the 4th day after the treatment with

inflammatory stimulus. As shown in Figure 6.2, first, the cells were loaded with 500 µl
of Fluo-3 loading solution. The loading solution constitutes warm Locke’s solution with
Fluo -3 dye (1:500) and Pluronic acid (1:1000). The cells were treated with this solution
for 1 hour at 37 °C, in a 5% CO2 incubator. After an hour of incubation, the loading
solution on the cells was pipetted out and the cells were treated with 500 µl of recovery
solution which constitutes Locke’s solution warmed at 37 ºC. The cells were incubated in
the recording solution for 45 mins at 37 º C, in 5% CO2. The recovered cells were
stimulated with three different agonists, ATP 100 µM, Glutamate 100 µM, and
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Ionomycin 1 µM to induce calcium signaling. Fluorescent intensity changes in the cells
in real-time corresponding to the calcium influx due to stimulation via agonist were
imaged and recorded in real-time under the inverted microscope (Olympus CKX41) with
a 488 nm excitation wavelength filter at a frame rate of 4 seconds. The experiment was
visualized and recorded in the Intracellular Imaging software.

Figure 6. 2: Experimental layout for calcium imaging in BMVECs, Astrocytes, and in
their co-culture model after treatment with the inflammatory stimulus, a combination
of TNF and LPS.
6.2.4.3

Measuring and Analyzing Calcium Fluorescence Intensity
Calcium fluorescence intensity was measured and analyzed as mentioned

above in Section 6.2.3.2.
6.3

Results

Calcium Activity in BMVECs and Astrocytes After Treatment with NO
Donor
The Ca++ peak response was upregulated in the BMVECs pre-treated with Dserine for 90 minutes before imaging, compared to the BMVECs controls (Figure 6.3 (a)
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and (b)) for stimulation of 100 µM ATP. For cells treated with sodium nitrite alone, the
peak calcium was conspicuously higher and came down quicker than the controls (Figure
6.3 (c)) while the Ca++ peaks for the cells treated with sodium nitrite in presence of Dserine resulted in a significant number of calcium oscillations clearly distinguishable by
visual observations (Figure 6.3d).

Figure 6. 3: Calcium signals recorded for BMVECs when stimulated with agonists
ATP 100 µM, Glutamate (Glu) 100 µM and Ionomycin (Iono) 1 µM in A) Controls
B) Cells treated with D-serine alone, C) Cells treated with sodium nitrite alone, and
D) Cells treated with a combination of D-serine and sodium nitrite. The X-axis
represents time and Y-axis represents normalized fluorescent intensity values.
The reproduction of the same experiment with astrocytes showed that astrocyte
culture was more responsive to glutamate (100 µM) stimulation after ATP compared to
the BMVECs when treated with D-serine (Figure 6.3b and Figure 6.4b). The astrocyte
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response to both sodium nitrite treatment alone, and in presence of D-serine was
significantly reduced compared to the results found in BMVECs with no conspicuous
difference found for the treatment conditions when compared to controls.

Figure 6. 4: Calcium signals recorded for astrocytes when stimulated with agonists
ATP 100 µM, Glutamate(Glu) 100 µM and Ionomycin (Iono) 1 µM in A) Controls,
B) Cells treated with D-serine alone, C) Cells treated with sodium nitrite alone, and
D) Cells treated with a combination of D-serine and sodium nitrite. The X-axis
represents time and, Y-axis represents normalized fluorescent intensity values.
Table 1: Database showing a total number of cells, frames, and data points analyzed for
BMVECs and astrocytes to study the effect of NO donor in calcium activity of the cells.
BMVECs Culture
Astrocyte cultures

Data
Frame
Total cell
123,138
1766
1396
36,604
992
550
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As observed in Figure 6.3 significant changes in calcium signals were recorded in
BMVEC cultures for the different treatment condition considered and therefore the
calcium signals were further analyzed for quantifying the peak fluorescence intensity that
corresponds to peak calcium influx in the cell, the number of oscillating cells, time taken
per oscillation, and the time taken for the signal to decay to baseline, for all the treatment
conditions in the experiment. However, astrocytes did not show notable calcium changes
for the treatment (Figure 6.4) as was observed for BMVECs and hence the data were not
analyzed for obtaining further information as in the case of BMVECs.
In BMVEC cultures, the results were analyzed for all the cells that showed
calcium response above the normalized threshold fluorescence values i.e. 1.2 or 20%
above baseline for ATP stimulations. Peak Ca++ response of BMVECs cells with ATP
stimulation was 21.3%, 42.7%, 54.3%, and 346% above baseline for BMVECs controls,
treated with D-serine alone, nitrite alone, and the combination of nitrite and D-serine,
respectively, with corresponding mean peak fluorescence intensity values of 1.21,1.42,
1.54, and 4.4 (Figure 6.5a). Hence, cells treated with NO donor sodium nitrite in
presence of D-serine showed significantly increased peak calcium response compared to
all other conditions, while the cells treated with D-serine alone showed around 2-fold
increase and cells treated with nitrite alone showed a 2.5-fold increase in peak calcium
response, compared to the control BMVECs.
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Figure 6. 5: Graph showing results for calcium signal analysis for BMVECs cells
controls, treated with D-Serine (DS), Sodium Nitrite (NO2 ), and a combination of DS
and NO2. A) Normalized Peak fluorescence intensity B) Time is taken per oscillation
for each treatment condition, C) Percentage of cells above the threshold for
fluorescence intensity(1.2) Vs percentage of oscillating cells and D) time taken for
the signal to decay. The data represents an average of 3 experiments (N=3) with n= 27
to 114 number of samples (cells) in an experiment. The error bar represents SEM
values and ‘*’ represent p<0.5.
The time taken for each oscillation/flickering with a peak above or on the baseline
for ATP stimulation was analyzed for each condition of treatment and was found to be at
28.6, 20.3, 18.29, and 14.27 s per oscillation for BMVECs controls, treated with Dserine alone, nitrite alone and the combination of nitrite and D-serine respectively
(Figure 6.5 (b)), thus showing that cells treated with nitrite in presence of D-serine
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exhibited more oscillations and higher frequency compared to all other conditions, as the
frequency is inversely proportional to period (f=1/T).
For BMVECs controls, treated with D-serine alone, nitrite alone, and the
combination of nitrite and D-serine, the percentage of cells above the threshold were
found to be at a mean of 37.5%, 31.8%, 28.4%, and 42.5%, respectively per ROI, while
the percentage of oscillating or flickering cells were found to be 29.5%, 26.5%, 14.5%
and 38.5%, respectively (Figure 6.5c). The result suggests that the cells treated with NO
donor, sodium nitrite in presence of D-serine have a higher number of cells oscillating as
well as responding to the ATP stimulation compared to all other conditions while
strikingly, cells treated with sodium nitrite alone had the least number of cells responding
and oscillating to the stimulation.
The calcium signals recorded were also analyzed for the time taken for the
calcium response to come to the baseline after the occurrence of the peak, termed as the
decay of the signal. The times taken for the Ca++ signal to decay were found to be 58.6,
53.3,53.3, and 162.6 s for BMVECs controls, treated with D-serine alone, nitrite alone,
and the combination of nitrite and D-serine, respectively (Figure 6.5d), thus suggesting
that the Ca++ signals recorded for BMVECs treated with nitrite in presence of d-serine
stayed for considerably higher time and cells were active for longer time point for the
same ATP stimulation compared to all other conditions where the signal decayed to
baseline by nearly same time point.
The total number of cells, frames, and data points analyzed is shown in Table 2.
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Table 2: Database showing a total number of cells, frames, and data points analyzed per
treatment condition to study the effect of NO in calcium activity in the endothelial cells
per the condition of treatment.

6.3.2

Data Point

Frame

Total cell

Control

21,301

338

251

DS treated

19,944

301

249

NO2 treated

30,385

350

342

DS+NO2 treated

34,249

395

339

Calcium Activity in BMVECs, Astrocytes, and Co-culture Model Treated

with Inflammatory Stimulus.
Figures 6.6 and 6.7 show images of cells recorded during calcium imaging for
BMVECs cells and co-culture model, respectively. Figure 6.6 shows the images of cells
representing peak calcium response for ATP stimulation for normal cells and cells
induced with inflammation. The cells treated with inflammatory stimuli showed the
characteristic morphological changes (lumens in between cellular networks) observed in
Chapter 4 and significantly higher fluorescence intensity compared to the control cells.
Figure 6.8 shows the periodic images for co-culture model controls, before and after
stimulation with agonist ATP and ionomycin.
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Figure 6. 6: Images showing the difference in cell morphology and fluorescence
intensity at peak calcium response to ATP stimulation for BMVECs - A) control and
B) treated with inflammatory stimulus.

Figure 6. 7: Peak Fluorescence intensity in Co-culture model A) before
stimulation B) after ATP stimulation and C) after ionomycin stimulation, showing
networking between BMVECs and astrocytes in the culture, clearly visible during
calcium imaging.
The Ca++ peaks recorded for BMVECs cells shows that the cells stimulated with
the inflammatory stimulus (TNF+LPS), which showed excessive NO release in Section
4.3.1 exhibited significantly higher calcium influx with notable Ca ++ oscillations
compared to controls cells when stimulated by 100 µM of ATP (Figures 6.8a and 6.8b).
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Figure 6. 8: Calcium dynamics in [1] BMVECs –A) Controls B) Stimulated ; [2]
Astrocytes– C) Controls D) Stimulated; [3] Co-Culture - E) Controls F) Stimulated,
in response to agonists ATP, Glutamate and Ionomycin. The X-axis represents time ,
Y-axis represents normalized fluorescent intensity values
The astrocytes were less responsive to the ATP stimulation than the BMVECs
control cells (Figures 6.8a and 6.8c). In line with the results observed for BMVECs,
astrocytes also showed a slight increase in Ca++ in the cells treated with inflammatory
stimulus compared to astrocyte controls in response to ATP stimulation (Figures 6.8c
and 6.8d), but for cells treated with the inflammatory stimulus, the disparity between the
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Ca++ increase in BMVECs was nearly threefold higher for BMVECs cells when
compared to the astrocytes as shown in Figures 6.8b and 6.8d. Astrocytes seem to be
more responsive to stimulation of glutamate 100 µM (after ATP 100 µM) compared to
BMVECs Figures 6.8and 6.8c, while the difference in glutamate stimulations for both
controls and stimulated cells was not significant enough as was observed for ATP. In the
co-culture model, the Ca++ influx for the same stimulation of ATP (100 µM) showed
significantly inhibited calcium response compared to BMVECs treated with the
inflammatory stimulus (Figures 6.8b and 6.8f). The average Ca++ influx was seen
slightly higher or at a similar level as was observed for astrocytes.
Peak calcium response, the total number of cells per ROI, and the percentage of
cells responding to the ATP stimulation were further analyzed for BMVECs, astrocytes,
and the co-culture model.
6.3.2.1

Peak calcium response
Figure 6.9 presents the analysis of peak calcium response that corresponds to the

normalized fluorescence intensity values above baseline (before stimulation), showed a
10-fold increase in BMVECs cells stimulated with inflammatory cells compared to the
BMVECs control cells with 139% and 13% increase respectively in mean peak Ca ++
response from baseline. In the case of astrocytes, the peak calcium response for cells
stimulated with the inflammatory stimulus was around 3-fold higher than for the control
cells with a 14% and 4% increase in mean peak calcium response, respectively, above the
baseline. When compared to the BMVECs the mean peak calcium influx for stimulated
astrocytes was found to be around 10-fold less than was observed for stimulated

91
BMVECs, while the astrocytes control response was reduced by approximately 3-fold
compared to BMVECs control cells.

Figure 6. 9: Peak calcium response analysis in Control cells (Blue) and cells
stimulated with the inflammatory stimulus (Red) for BMVECs, astrocytes, and their
Co-culture model, in response to ATP stimulation. Data represent the averages of
N=3 experiments with two wells per condition, and no. of samples (cells) ranging
from n= 40 to 211. Error bars represent SEM values, ‘**’ represents p<0.01, and ‘*’
represents p<0.5.
In the co-culture model, the peak calcium response was found to be at 15% and
63%, respectively, for controls and cells stimulated with inflammatory stimulus. These
values show that calcium response for co-culture lies in between the two individual cell
cultures and shows 76% inhibition compared to the BMVECs monoculture and a 49%
increase compared to astrocyte monoculture. Thus, the results indicated that the
stimulated cells show significantly higher calcium influx in all conditions i.e.,
monocultures of BMVECs and astrocytes as well as their co-culture, compared to the
cells at normal physiology (controls). The BMVECs culture shows excessive calcium
influx compared to normal cells, which is a sign of calcium dysregulation as was
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observed in neurons when treated with TNF (178), which is caused by the expression of
voltage-sensitive calcium channels in neurons, leading to hyperactive calcineurin activity
and synaptic depression. This dyshomeostasis of Ca ++ in BMVECs was balanced in the
presence of astrocytes in the co-culture model, as the peak calcium response for
stimulated co-culture model was enhanced compared to the co-culture controls but was
significantly inhibited compared to the stimulated BMVECs culture. These results
indicate that astrocytes have a role in balancing the excessive calcium influx in BMVECs
during inflammation.
6.3.2.2

Cellular Population Response to Ca++ influx

The stimulated BMVECs cells had a mean total of 122 cells per ROI, which is
significantly higher compared to 83 cells for controls per ROI analyzed (Figure 6.10A).
Out of the cells present in the ROIs, a mean of 94% (687 of 731) of the stimulated cells
responded to the ATP stimulus, while a mean of 87% (432 of 496) control cells responded
to ATP (Figure 6.10B). These results suggest that the high Ca++ influx in BMVECs is
supported by a significantly higher percentage of cellular response. The astrocytes also
showed a higher number of cells per ROI for cells stimulated with the inflammatory
stimulus with an average number of 75 cells for stimulated and 56 for control conditions
(Figure.6.10A). These average numbers of cells per ROI for astrocytes were significantly
smaller than the values observed for BMVECs. As astrocytes are normally larger and
flatter than BMVECs, less cells cover larger surface area under their normal physiology.
A high percentage of cells responded to the ATP stimulus with a mean of 96% of cells
(289 out of 301) in ROI responding to ATP, which is significantly high compared to
controls where a mean of 66% of cells (149 out of 225) responded to the ATP stimulus
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(Figure.6.10B). These results verify that the cellular response to ATP is significantly
high for stimulated conditions in both BMVECs and astrocytes with higher calcium
influx as wells as a larger population of cells responding to the ATP stimulation.

A)

B)

Figure 6. 10: Results for A) Mean number of cells present B) Percentage mean of
cells responding to ATP stimulus; per ROI for BMVECs, astrocytes, and coculture model. Data represent the averages of N= 3 experiments with two wells
per condition, and no. of samples (cells) ranging from n= 40 to 211. Error bar
represents SEM values, ‘**’ represents p<0.01, and ‘*’ represents p<0.5.
In line with the BMVECs and astrocyte culture, the co-culture model also showed
a higher cell count per ROI with an average of 125 cells for stimulated cells compared to
93 cells for the control cells. These results verify that inflammatory stimulation used for
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the experiment helps to increase the proliferation of cells in the system as shown in
Section 4.3.3. An interesting observation in the co-culture model was found in the case
of the percentage of cells responding to the ATP stimulation. The co-culture shows no
significant difference in percentages of cells that responded to ATP stimulation as the
averages are around 77% for both control (428 out of 556) and stimulated (576 out of 748
cells) conditions, unlike BMVECs and astrocytes, where significantly higher percentages
of stimulated cells responded compared to controls. Further, the percentage of cells
responding to ATP also lies in between the percentages observed for BMVECs and
astrocytes. These observations reinforce the results that presence of astrocyte provides
negative feedback to the high calcium response observed in BMVECs as an act of
balance of inflammatory effect on overall cellular networks in the culture and not merely
the action of a certain population of cells.
A total number of cells, frames, and data points, as shown in Table 3, were
recorded for BMVECs, astrocytes, and co-cultures for studying the calcium response in
BBB during inflammation.
Table 3: Database used for studying calcium response in BBB cells and their co-culture
model when stimulated with the inflammatory response (100 ng/ml of TNF +5µg/ml of
LPS)

Data Point

Frame

Total cell

BMVECs Culture

157,855

1567

1725

Astrocyte cultures

42,351

661

637

Co-cultures

145,941

1276

2018
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6.4

Conclusion and Discussion

Calcium and neuroinflammatory signals exhibit cross-talk and bidirectional
interactions, though they are distinct in many ways (178) and NO is one such
inflammatory signal. Figure 4.1 showed that even the astrocytes, the low NO producing
cells in the system, can produce 5 µM of sodium nitrite (NaNO 2). This research finds
that treatment of BMVECs with 5 µM of sodium nitrite in the presence of d-serine, can
produce enhanced calcium response and a significantly higher number of calcium
oscillations, while the same treatment in astrocyte does not produce any significant
difference in the calcium response. Coactivation of NMDA receptor by glutamate and dserine increased vasodilation in eNOS dependent mechanism (177), and in our
experiment we observed enhanced calcium response to NO and d-serine treatment in
endothelial cells, thus showing the modulatory activity of NO for calcium signals is
possibly mediated by NMDA activation in endothelial cells which might be central to
NVC since intracellular Ca++ has been known to drive NVC. Enhanced calcium influx at
BBB may modulate barrier permeability, and therefore it might be a cue on NO-mediated
BBB permeability(179).
When the calcium response was studied in presence of inflammatory stimulus in
cells, BMVECs showed excessive calcium influx in stimulated cells, indicating calcium
dysregulation in cells which is a determining factor for brain cell death and degeneration.
This uncontrolled increase in calcium was significantly inhibited in the coculture model
by the presence of astrocytes, indicating that astrocytes can produce a negative feedback
mechanism to the calcium dysregulation in BMVECs during inflammation, which can
prevent Ca++ and neuroinflammation-related brain cell death and degeneration.

NANOMATERIALS AS CARRIERS FOR
INTRACELLULAR DELIVERY ACROSS BLOOD BRAIN
BARRIER CELLS

7.1

Introduction

Neurological and mental disorders are some of the most poorly treated diseases
currently, impacting the lives of people of all ages and growing the chances of premature
death. Epilepsy, Alzheimer’s, Parkinson’s, multiple sclerosis and ALS are common
examples of neurological disorders that have affected 1 billion of the human population,
with nearly 1 out of 6 people suffering from these diseases (121). Thus, if these disorders
could be treated through various techniques such as nanotechnology, up to 70% of
diagnosed patients could be cured (180–182).
The brain microvascular endothelial cells (BMVECs) in the blood-brain barrier
constitute the tight junction proteins in between the cells which along with other unique
features of BMVECs, as stated in Section 2.1.1, provide selective permeability to BBB.
Thus the BBB prevents the entry of pathogens and other toxic substances into the brain,
but at the same time, prevents most potential drugs against neurological and mental
disorders to cross the barrier and readily reach into the brain tissue (21). In this research,
we studied the potential application of naturally available, environmentally friendly
halloysite nanotubes (HNT) as a carrier for drug delivery across the endothelial cells.
HNTs are hollow clay capsules, 50 nm in diameter, that can deliver the drug-loaded in its
96
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lumen. They are formed by 10–15 revolutions of 0.7 nm thick kaolin aluminosilicate
sheets with diameters at a range of 50 and 60 nm, lumen diameters of 12–15 nm, and
lengths of 500–900 nm (183,184). The outer surface of HNTs is composed of SiO 2, and
the inner surface is composed of Al2O3, which are oppositely (negative/positive) charged
in the pH range of 3–9. The HNT structure shown in (Figure 7.1) shows how payloads or
drugs can be loaded in the positively charged lumen that is efficient in adsorbing
negatively charged drug molecules spontaneously.

c

d

Figure 7. 1: A TEM and SEM image of halloysite nanotubes (a and b). Schematic of
halloysite nanotube depicting characteristics and dimensions of halloysite nanotubes
(c and d) (18) .
This chapter uses fluorescence microscopy to study binding and penetration of
HNTs tagged by fluorescent rhodamine B isothiocyanate dye (RITC) into BMVECs for
better visualization of cellular interaction or penetration of HNTs and their delivery
properties. Further, it discusses the testing of HNTs loaded with ionomycin, a calcium
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ionophore (185), for brain cell stimulation to monitor real-time calcium transport across a
membrane that exhibits the real-time delivery properties of HNT-ionomycin
formulations. Ionomycin was selected for loading and delivery studies because it has
well-known antibiotic property and might be able to induce cancer cell death and inhibit
proliferation (186,187). All experiments related to HNTs were performed in collaboration
with Mahdi Saleh from Dr. Lvov’s lab, where part of the work related to HNTs
processing and loading with RITC and ionomycin was performed by him. This chapter
also includes a brief report on cellular uptake of a novel cationic peptide ‘L57’ in
BMVECs cells to explore their potential as a carrier across blood brain barrier (188). The
experiments related to ‘L57’peptide were performed in collaboration with Jolin
Rodrigues from Dr. Murray’s lab.
7.2

Materials and Methods

Figure 7.2 shows the overall experimental layout for studying HNTs loaded with RITC
and ionomycin for their potential as drug delivery vehicle across BBB by using
fluorescence microscopy, calcium imaging system and MTT assay. The following
sections explain the methods in detail.
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Figure 7. 2: Schematics showing loading clay nanotubes with fluorescent rhodamine
(RITC) and ionomycin and treating the endothelial cells with the loaded nanotubes.
[1] HNT-RITC route monitored with Fluorescence Microscopy, [2] HNT-Ionomycin
route monitored using Calcium Imaging System and [3] Cytotoxicity assessment of
HNTs using MTT assay.
7.2.1

Preparation of HNT-RITC and HNT-Ionomycin Formulations
Three samples of HNTs, loaded as 10 mg halloysite/1 mL DI water per 0.5, 1, and

2 mg of RITC were obtained from Dr. Lvov’s lab at Louisiana Tech University.
Halloysite samples were prepared by loading RITC and ionomycin through stirring,
centrifugation, and sonication. For HNT-ionomycin formulation, 20 mg of HNTs were
stirred with a 1 µM final concentration of ionomycin for 24 hours. The solutions were
then sonicated and vortexed for 1 min, then mixed on a stir plate for 24 h at room
temperature. The mixture was washed once by centrifugation at 2500 RPM for 2.5 min
and then dried at 70 ºC for 24 h. The mixture was then washed with sterile water by
centrifugation 2500 RPM for 3 min. The solution was then freeze-dried for 20 min and
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placed in a vacuum for 24 h to remove the excess solution. Samples were then
characterized by the zeta potential analyzer, which displays the surface charge and
thermogravimetric analysis, allowing us to calculate the loading percentage.
7.2.2

Cell Treatment with HNT-RITC Formulations
The BMVECs were isolated from cortical glial culture as mentioned in Section

3.1. BMVECs thus obtained were plated at the density of 10k per mL in 48 well cell
culture plates and grown in vitro at 5% CO2 and 37 ºC. When the cells reached ~60%
confluency, they were treated with 10 µg/mL of three different samples of HNT-RITC
formulations, each with a loading ratio of 1:20,1:10 and 1:5. Cells treated with media
alone were used as controls for determining cellular toxicity and change in morphology.
Cells treated with RITC alone were used as positive controls for fluorescence. Cells
treated with empty halloysite tubes were used as negative controls for both BMVECs
stimulation and RITC experiments. The treated cells were incubated for three different
time points, 30 mins, 4 hours, and 24 hours, to analyze the efficiency of fluorescent
tagging and delivery of RITC from HNTs over time.
7.2.3

Digital Microscopy
After the predetermined incubation period with HNTs loaded with RITC, all the

controls and experimental wells were washed twice with 250 µL of warm 1X PBS, which
was replaced by 300 µL of phenol red-free RPMI media, warmed at 37 ºC, before
imaging them live using Digital Microscopy (Leica DMI 6000B). Three images per well
were captured for 3 wells per condition of treatment for 3 different experiments to
observe the binding and penetration of halloysites in the BMVEC cells and the delivery
of RITC into the cells.
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7.2.4

Cell Stimulation with HNT-Ionomycin Formulations
For BMVECs stimulation with HNT-ionomycin formulations, cells were grown in

vitro at 5% CO2 and 370C until they reach confluency ~70%. Two concentrations
(10 µg/mL and 50 µg/mL) of HNT-ionomycin formulations were used to stimulate the
cells. Empty halloysite nanotubes (50 µg/mL) as negative controls and 1 µM of
ionomycin as positive control were also used for stimulating the cells. Figure 7.3
presents a schematic for BMVECs cell stimulation using HNT loaded with ionomycin
and signal recording using calcium imaging system.

Figure 7. 3: Schematics illustrating the loading of ionomycin inside the lumen of
halloysite nanotubes and stimulating cells on top of the calcium imaging system for
capturing real-time calcium events due to delivery of ionomycin from HNTs into the
brain endothelial cells.
The cells were loaded as mentioned earlier in Section 6.3.2.1 and Appendix C.7.
The cells were incubated with loading solution for 1 h at 5% CO 2 and 37 ºC in a
humidified incubator and then with 500 µL of recovery solution for another 1 hour. The
recovered cells were then stimulated with halloysite loaded with ionomycin (10 and 50
µg/mL), halloysite alone (50 µg/mL), ATP 100 µM, and ionomycin 1 µM at different
instances depending on the experimental design. Real-time intracellular calcium (Ca ++)
change caused by ionomycin transport across the cell membrane was recorded by
capturing images every 4 seconds with InCyt Im1 software on the imaging system. The
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images were then used for measuring and analyzing calcium fluorescence intensity as
mentioned in Section 6.2.3.2. This technique uses the change in fluorescence intensity as
the function of time as a measure for quantifying calcium changes in cells which
corresponds to the delivery of ionomycin from halloysite nanotubes.
7.2.5

MTT Assay
The MTT assay is described in Section 5.2.4, and Appendix H.

7.2.6

Cellular Uptake of Fl-L57 Peptide
L57 peptide was purchased from Biomatik (Cambridge, ON, Canada).BMVECs

and astrocytes were plated at a density of 10,000 cells per well and grown at 37 ºC and
5% CO2. When the cells reach ~50 to 70% confluency, cells were treated with FITC
(fluorescein isothiocyanate)-labeled L57 (FL-l57) peptide at 3, 10 and 30 µM
concentrations for 4 hours, and uptake was visualized by taking images under
fluorescence microscope (Leica DMI 6000B).
7.3
7.3.1

Results

Cell Treatment with HNT- RITC Formulations
Halloysite binding and penetration into the endothelial cells were visualized as

red fluorescence concentrated within the cells, Figure 7.4. The addition of RITC dye
alone did not color the cell's interior within 30 min of treatment, while the dye-loaded
halloysite bound or penetrated the cells and started releasing the dye inside the cells,
coloring them red. Within a 4-h time frame, RITC and RITC-HNT both showed cells
with more fluorescence compared to the same samples in the 30 min exposure time
(Figure 7.5). Furthermore, RITC-HNT formulations displayed greater fluorescence
compared to RITC only, demonstrating the dye delivery from HNT into the cells. The
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loading of RITC in HNTs shown are 5 wt % (1:20) and 20 wt.% (1:5), and the
concentration used for RITC alone controls shown is equivalent to 20 wt % HNT
samples.
The small bright dots seen in the images of Figures 7.4, 7.5, 7.7 and 7.8 are the
aggregated halloysite tubes that contain RITC. HNT-RITC aggregation is displayed
mostly along the cellular membrane and inside the endothelial cells as indicated by
nuclear exclusion. Therefore, halloysite nanotubes can encapsulate, transport, and slowly
release the dye (or drugs as we will show with an example of ionomycin) over 24 hours.
An important consideration is that the surface of the halloysite was not modified with any
type of polymer or silane coating.
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Figure 7. 4: Fluorescent (Left) and Phase (Right) images of endothelial cells treated
with halloysite nanotubes loaded with RITC dye after 30 mins of exposure, for
samples with loading ratio 1:20 (A-B), loading ratio 1:5 (C-D) and RITC only (E,
F).Magnification 200X,scale bar=100µm
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Figure 7. 5: Fluorescent (Left) and Phase (Right) images of endothelial cells’
treatment with halloysite nanotubes loaded with RITC dye (samples) after 4 hours
of exposure for cells treated with HNT-RITC( loading ratio 1:20) [A-B], cells
treated with HNT-RITC( loading ratio 1:5) (C-D) and cells treated with RITC
alone. Magnification 200X,scale bar=100µm
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Figure 7. 6: Fluorescent (Left) and Phase (Right) images of endothelial control
cells after 4 hours of exposure - with no treatment [A-B], and treated with
halloysite alone [C, D]. Magnification 200X,scale bar=100µm
Results for the 24-h treatment showed more profound fluorescence in both
conditions but RITC-loaded halloysite delivered more dye into the cells at every period as
compared to just the dye alone (Figure 7.7). Images at a time point of 24 h displayed the
nanotubes distribution more evenly over the cell interior, still contained within the cell
body (Figure 7.8G). RITC-HNT are concentrated in some smaller spots of ca. 1 µm
dimeter, which may be the nuclear surrounding, as was found for MCF-7 cells treated with
halloysite (Vergaro et al., 2010). Throughout the trials, we detected a nuclear exclusion,
extended length of fluorescence, and that the tubes did not stress or kill the cells. The clay
nanotubes are displayed as small dots in and are brighter than the dye spread inside the
cells.
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Figure 7. 7: Fluorescent (Left) and Phase (Right) images of endothelial cells’
treatment with halloysite nanotubes loaded with RITC (samples) dye after 24 hours of
exposure for cells - treated with HNT-RITC( loading ratio 1:20) [A-B], treated with
HNT-RITC (loading ratio 1:10) [C-D], treated with HNT-RITC( loading ratio 1:5)
[E-F] and treated with RITC alone(control) equivalent to loading ratio 1:5.
Magnification 200X,scale bar=100µm
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After cell fixation (4 days), cells treated with dye only were washed away with only
minimal fluorescence remaining on the cells. The HNT-RITC treated cells still
showed significant fluorescence up to 11 days of observation, indicating a prolonged
delivery of the dye from the clay nanotubes (Figure 7.8).

Figure 7. 8: Fluorescent Images of endothelial cells treated with halloysite
nanotubes loaded with RITC dye after 11 days of exposure, for samples with
loading ratio 1:10 (A) and RITC only (B).Magnification 200X,Scale bar=100µm
7.3.2

Delivery of Ionomycin – Halloysite Formulations into BMVECs

Figure 7. 9: Images captured in the calcium imaging system for BMVECs at (A) no
stimulation (baseline); (B) peak stimulation by 50 µg/mL of empty halloysite nanotube,
and (C) peak stimulation by 50 µg/mL nanotubes loaded with ionomycin. Magnification
= 200X.
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Figure 7.9 shows us the images captured during real-time calcium imaging of
BMVECs before and after stimulation with empty HNTs and HNTs loaded with
ionomycin. A series of images captured at the interval of 4 seconds each were analyzed to
obtained calcium signals, as shown in Figure 7.10.
From real-time calcium imaging, the cell's response to ionomycin had a spiked
increase in Ca++, which decayed quickly due to clearance by cells as shown in baseline
(Figure 7.10A). When ionomycin was encapsulated with halloysite, we achieved a higher
response of Ca++ for the same concentration (1 µM) loaded that was also used for the
control, resulting in a gradual rise in Ca++, which remained at higher level for a longer
period until it was diluted by the addition of any other stimuli. This increase of Ca ++
indicates the gradual and prolonged transport of ionomycin through halloysite across the
cell membrane (Figures 7.10B and C).Cell stimulation with empty halloysite nanotubes
led to only a small response (Figure 7.10D). To ensure that the cells were healthy and
responding normally to other physiological stimuli, cells were tested with ATP, a wellknown stimulator for BMVECs (Figures 7.10E). Cells that responded to ATP showed a
significant peak that is normally observed for BMVECs, ensuring normal physiology of
the stimulated cells . Each experiment was ended with ionomycin stimulation to
demonstrate that the cells were still responsive to Ca++ changes, ensuring no cell death,
and avoiding the occurrence of false signals during the experiments. Ca ++ peak analysis
presented in Figure 7.10 indicates that stimulation by ionomycin (positive control) shows
an instant peak of Ca++ that decays quickly compared to HNT-ionomycin nanocapsules
(10 and 50 µg/mL), which shows a gradual influx of Ca ++ and a higher delivery of
ionomycin in the cells for both concentration (Figures 7.10 B and C). Stimulation by
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halloysite alone can produce a slight Ca++ response, significantly less compared to HNTionomycin formulations, that show significant increase in Ca ++ response for the use of 10
µg/ml, which can be enhanced further with the stimulations by higher concentrations of
HNT-ionomycin.

Figure 7. 10: Ca++ peak intensity obtained for different stimulation on BMVECs, in
the horizontal axis is the image number indicating periods with a total range of 4 s
each (1 image no. = 4 s); and in the vertical axis is the normalized values for
fluorescence intensity corresponding to calcium activity (A) stimulated by ionomycin
(Iono) 1 µM (positive control); (B)stimulated by 10 µg/mL and 50 µg/mL of HNTionomycin (sample tested);(C) stimulated by 50 µg/mL of HNT- ionomycin (D)
stimulated by 50 µg/mL of empty HNTs (negative control) and (E) stimulated by
ATP, a well-known Ca++ stimulator (positive control indicating healthy cells),
followed by HNT-ionomycin formulation (10 µg/mL) showing the comparison
between the Ca++ responses of physiological stimulation (ATP) and HNT-ionomycin
formulation for the same cells. The X-axis represents time and shows total time the
Ca++ signals were recorded , Y-axis represents normalized fluorescent intensity
values.
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7.3.3

Statistical Analysis of Calcium Response to Different Stimuli
The graphs in Figure 7.10 show signals obtained for only 3 cells for each

condition for simplification and clear representation of the data. The number of cells
captured per frame for a condition being tested in an experiment act as a ROI, and it
ranged from 41 to 140 cells. After obtaining the calcium signals for different
stimulations, the Ca++ fluorescence intensity data as a function of time were used to
extract the various information as shown in Figure 7.1,1 namely percentage of peak Ca++
response above the baseline (Figure 7.12), time taken for the stimuli to reach the peak
response (Figure 7.13), and the number of cells that responded to the stimuli (Figure
7.14). Overall, 1,232 cells were analyzed for the results reported for calcium imaging.

Figure 7. 11: The signal explanation scheme that elucidates various parameters
analyzed for the calcium signals recorded after the stimulations of cells (18).
The results for calcium signal analysis shows that the increase in peak calcium
response above the baseline was 120% for HNT-ionomycin (50 µg/mL), and it was
significantly greater than for ionomycin alone (positive control) which was at 82%. The
halloysite (negative controls) showed a slight Ca++ response of 16% above baseline. The
results that the nanotubes alone can cause some Ca++ response suggest that some form of
cellular interaction and communication between the nano clay and endothelial cell
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networks is served by the signaling molecule, calcium. For ATP stimulation the peak
response was 40% above baseline, which indicates ATP response in normal physiological
conditions of cultures used (Figure 7.12).

Figure 7. 12: Increase in peak calcium response in percentage for each stimulus used
to stimulate the BMVECs, averaged over three experiments (N=3) for each
stimulation, with n= 41 to 140 cells analyzed per experiment. Error bar represents the
standard deviation between the experiments and “***” represents p<0.001.
Figure 7.13 represents the time taken for the cells to produce the peak calcium
response. It tells us how delayed or instantaneous the peak response was, indicating the
delivery properties of halloysite clay nanotubes. The duration of release until peak
calcium response after the stimulation was found to be 80 s for the nanoclay loaded with
ionomycin at 10 µg/mL, 54 s for halloysite loaded with ionomycin at 50 µg/mL, and 66 s
for 50 µg/mL halloysite alone. This result, along with results in Figure 7.10 A, B and E,
explains that a low concentration 10 µg/mL HNT-ionomycin formulation is enough to
enhance delivery of ionomycin for a prolonged time as compared to ionomycin itself. A
higher HNT concentration (50 µg/mL) can increase this response further, but the delay is
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better achieved with the use of lower concentrations. In contrast, the duration was very
short for ionomycin 1 µM at 13 s and ATP at 16 s. The duration was found higher for the
halloysite-loaded and unloaded samples as compared to ionomycin and ATP in their
soluble forms. This higher duration indicates delayed diffusion from the nanotubes
caused by the faster release of soluble ionomycin and ATP. Overall, the halloysite loaded
with ionomycin showed delayed and gradual release of ionomycin into the cells and once
it reaches the peak response it continues to diffuse for a prolonged time which is expected
to be up to 24 hours as was observed for the nanotubes loaded with RITC (Figures 7.7).
A 24-hour treatment of BMVECs with ionomycin concentration of 1 µM that was used
throughout the experiment did not show any cytotoxicity to the cells.

Figure 7.13: The time taken (seconds) to reach the peak calcium rise after a
stimulation in the BMVECs, indicating how delayed the peak response is. The results
are averaged over three experiments (N=3) for each stimulation, with n = 41 to 140
cells analyzed per experiment. Error bar represents the standard deviation between the
experiments and “***” represents p<0.001.
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Figure 7. 14: The percentage of BMVECs responding to a particular stimulation.
The results are averaged over three experiments (N=3) for each stimulation, with
n= 41 to 140 cells analyzed per experiment. Error bar represents the standard
deviation between the experiments and “***” represents p<0.001.
Figure 7.14 represents the percentage of cells that responded to the given
stimulus in an experiment. A higher number of cells responded to the HNT – ionomycin
formulation with 97% for a concentration of 10 µg/mL and at 92% for 50 µg/mL, while it
was 65% for 50 µg/mL halloysite alone, 72% for 1 µM ionomycin, and 76% for 100 µM
ATP. This result indicates that all the parameters discussed here are supported by a high
response of cells, but the data specifically displays a higher value in the loaded samples
compared to the other conditions tested.
7.3.4

Lack of Toxicity Response of Halloysite Nanotubes in BMVECs
An MTT assay was performed 24 hours after treatment of the BMVECs cells

plated at 10k per ml when they reached 60% confluency to assess cell metabolism as the
measure of cytotoxicity. The results indicate that the empty halloysite nanotubes do not
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affect the cell metabolism in BMVECs and hence show no significant sign of toxicity as
the cellular metabolism was observed to be in a proximity of 1 to 2% more or less for the
treatment of 10, 25 and 50 µg/ml of HNTs, compared to control cells treated with media
alone (Figure 7.15). The positive control for toxicity, where 6 µg/ml of CuNPs were
added to the cells, showed inhibition of cell metabolism by 27% within 24 hours.

Figure 7. 15: Graph showing results for cytotoxicity testing of three different
concentrations (10,25 and 50µg/ml) of HNTs indicating no significant toxicity
imparted by HNTs on BMVECs by 24 hours of treatment. CuNPs were used as a
positive control for toxicity. Data represents an average of three experiments (N=2)
with triplicated wells(n=3). Error bar represents SEM values, “***” represents
p<0.001 and “*” represents p<0.05.
7.3.5

Cellular Uptake of Fl-L57 Peptides
Cells treated with Fl-57 peptides showed diffused staining throughout the cells for

both BMVECs and astrocytes. BMVECs incubated with 30 µM of Fl-57 exhibited
saturation of fluorescence. BMVECs showed significantly higher fluorescence and low
cytotoxicity and therefore significantly higher uptake of Fl-57 peptides, as shown by
Rodrigues et al. (186). Astrocytes showed comparably less fluorescence and therefore
less uptake than BMVECs as shown in Figure 7.16.
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Figure 7. 16: Fluorescence (Left) and phase (Right) images of cells treated with 10
µM of Fl-L57 peptides for BMVECs (A-B) and 30 µM of Fl-L57 peptides for
astrocytes (C-D) (188). Magnification=200X, scale bar=100 µm.

7.4

Conclusions

Halloysite nanotubes show great potential in delivering drugs effectively to the
brain as they were able to bind to the BMVECs and slowly release drugs over various
periods ranging from minutes to hours with no signs of toxicity to the endothelial cells of
brain micro vessels. The ability of halloysite to show enhanced, gradual, and prolonged
calcium response in brain microvascular endothelial cells when stimulated with the calcium
ionophore- ionomycin, compared to the use of ionophore alone (non-encapsulated) showed
real-time delivery characteristics of HNTs across the brain cell. Stimulation of BMVECs
with empty halloysite nanotubes was reported for the first time in this research. This
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recently discovered information suggests an approach to treating brain cancer cells through
drug delivery based upon the evidence suggesting inhibitory potential of ionomycin on the
cancer cells and its use as a chemosensitizer. We confirmed a delayed and prolonged
diffusion of the drug delivery mechanism when the cell probes (ionomycin+ RITC) were
loaded onto halloysite nanotubes. This loading provides a sustained delivery strategy for
drug penetration across the blood-brain barrier. Like HNTs, the lack of cytotoxicity and
high uptake of Fl-57 peptide observed on BMVECs exhibit the potential of the peptide as
a vector for drug delivery across BBB against CNS disorders.

CONCLUSION AND FUTURE DIRECTIONS
A large body of evidence suggests that astrocytes play a critical role in inducing
BBB attributes and functions by assisting in the proper expression and assembly of
intermolecular tight junctions, transporter proteins, and enzymatic pathways
(147,189,190). Astrocyte-secreted factors like VEGF, TGF-β, angiopoietin, glial-derived
neurotrophic factor are also known to be responsible for modulating BBB functions (4).
Hence, this research develops a co-culture model of BMVECs and astrocytes to create an
optimized BBB microenvironment while maintaining cellular communication to assess
the contribution of each cell type in the overall inflammatory response of BBB,
specifically for NO and calcium activity of cells, considering the physiological and
pathological significance of NO and Ca++ signaling in the brain. It also compares the
overall response to the monocultures of each cell type. When induced with the
inflammatory stimuli, the BMVECs cells produced an enormous amount of NO, in
contrast to the astrocyte cells which showed only a slight increase initially which
saturated over time. The cellular interaction between astrocytes and endothelial cells in
the co-culture model significantly reduced the NO synthesis compared to the BMVECs
monoculture, thus suggesting that astrocytes provide negative feedback to extreme NO
production from BMVECs during inflammation which otherwise can lead to
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peroxynitrite-related neurotoxicity or immune breach and BBB disruption related
neurological disorders.
This negative feedback function of astrocytes was further explored for the Ca ++
activity in the inflammation-induced co-culture model and compared with the Ca ++
activity in the individual cell types under normal physiology and when stimulated with
the inflammatory signal. A significant Ca++ dysregulation was observed in BMVECs
cells, which is generally an indication of brain cell death and degeneration and which was
balanced by the presence of astrocytes in the co-culture model, thus verifying the
negative feedback potential of astrocyte cells to the enhanced calcium activity in
BMVECs during inflammation. Ca++ changes were also measured for BMVECs cells by
treating them with a NO donor (NaNO2), to assess the effect of NO in the calcium
activity of BMVECs, in the presence and absence of d-serine, which showed significantly
enhanced calcium response and oscillations in the BMVECs due to NaNO 2 in presence of
d-serine.
Taking into consideration the huge research interest in therapeutics related to
exogenous NO delivery or NO catalysis in vivo for biomedical applications, this research
investigated the potential of CuHARS in NO catalysis in BMVECs cells during normal
physiology in presence of cystine nitroso thiol (CysNO) and when induced with
inflammation. CuHARS produced significant NO in presence of CysNO involving
constitutive eNOS in BMVECs, which is known for its beneficial role in the body while
it inhibited the iNOS produced during inflammatory conditions often known to have
harmful impacts in the body. Further CuHARS increased BMVECs metabolism and
inhibited glioma cell metabolism both in normal and inflammatory conditions, thus
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showcasing an extensive potential in drug delivery application in CNS. The HNTs loaded
with RITC and ionomycin separately, showed gradual and prolonged delivery of RITC
and ionomycin over time in BMVECs cells with no toxicity imparted to the cells like the
cell penetrating peptide (CPP) Fl- L57, which showed high uptake and no toxicity to the
cells. These results suggest HNTs and Fl- L57 as promising carriers for drug delivery
across BBB.

Figure 8.1: Schematics explaining the overall project summary
Although the testing of carriers on 2D in vitro cultures of BBB cells provided
evidence of biocompatibility and effectiveness in uptake and delivery of the materials to
the cells, questions about the carriers’ ability to bypass the inherent resistance of BBB
and deliver the payload to localized regions in brain remain to be explored. A multilayer
membrane of endothelial and astrocyte cells maintained across a permeating barrier as
shown in Figure 8.2 that closely mimics biological and structural complexities of the
BBB in vivo shall provide as a dependable and cost-effective tool for future
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developments on CNS drug delivery strategies implementing potential carriers HNTs,
CuHARS, CPPs and other nanomaterials.

Figure 8.2: Schematic presenting future direction towards testing permeabilities of
delivery vehicles (CuHARS, HNTs and CPPs) and their payload across blood brain
barrier by developing an in vitro BBB model using transwells.

APPENDIX A
A.1

TNF and LPS Stimulation on BMVECs

Figure A. 1: Bar graph showing the concentration of NO released by BMVECs
controls, controls inhibited by 1mM L-NAME (LN), BMVECs stimulated with the
inflammatory stimulus (a combination of 100ng/ml of TNF+ 5µg/ml of LPS),
stimulated cells with LN inhibition, BMVECs treated with LPS alone (5µg/ml) and
TNF alone (100ng/ml) for 2,4 and 6 DIV indicating that NO significant NO is
produced when cells are stimulated with LPS alone or TNF alone. Data represent
averages for three experiments(N=3) with four wells (n=4) per condition. Error bars
represent SEM values.
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A.2

Lumen Quantification Using Image Pro 7

A)

B)

Figure A. 2: Quantification of lumen formation in BMVECs – A) Controls and B)
Stimulated with inflammatory stimulus on 6 DIV, using Image-Pro 7 software.

A.3

Cytotoxicity on BMVECs with CuHARS Treatment

Two cell densities 3k and 6k cells per ml were plated on 48 well plates and incubated at 37
ºC and 5% CO2 for 3 days to provide them enough time for binding and growing on the
well plates. Both cell densities were treated on day 4 with 3 µg/ml and 6 µg/ml CuNPs
(positive controls) and 6µg/ml of CuHARs. Cell toxicity was observed under the
microscope and analyzed using the Diff-Quik staining technique.
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A)

B)

C)

D)

E)

F)

G)

H)

Figure A. 3: Comparison of Cytotoxicity between CuHARS and CuNPs on BMVECs
using Diff Quik staining technique after 24hours of treatment. The left panel shows
results for treatment in cells plated at 3k per mL and the right panel shows results for
cells plated at 6k per mL for -Controls (A-B), treated with 3µg/ml of CuNPs (C-D),
treated with 6µg/ml of CuNPs (E-F) and treated with 6µg/ml of CuHARS (G-H),
scale bar=100µm, Magnification:200X.
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Figure A. 4: Total count of cells (Nuclei) analyzed from Diff Quik staining for
treatment of 3µg/ml and 6µg/ml of CuNPs Vs 6µg/ml of CuHARS, showing higher
cell count at both 3k and 6k cell density and thus significantly low toxicity in
CuHARS treatment in BMVECs cells compared to the CuNPs treatment.

APPENDIX B
IMAGE-PRO PLUS VERSION 7.0
B.1

Calculating the Area of GFAP Staining from the Image

1. Insert the dongle (special security plug) that comes with Image-Pro Plus to unlock the
program.
2. Open Image-Pro Plus 7.0. A dialog box ‘Macro Browser’ appears. Click Done.
3. Go to File  Open  Select the image.
4. Go to Measure  Count/Size  Choose ‘Manual’  Click ‘Select Colors’  A
dialog box appears. Click ‘Color Cube-Based’  Select Class ‘1’  Under Options,
Select Sensitivity ‘4’  Pick ‘color picker tool’. Then click on the indigo blue color
staining (Start selecting the color from lightest to darkest)  Under Preview, select
‘Current Class’  Change to ‘Class Color on Black’ from ‘Class Color on Transparent’
 Select ‘Apply Mask’  Click ‘OK’.
5. Now choose ‘Automatic Bright Objects’ Click ‘Count’. The white area gets selected.
6. Go to ‘Measure’  Click ‘Select Measurements’  Choose ‘Area’  Click
‘Measure’.
7. Go to ‘View’  Click ‘Measurement Data’  Choose ‘Sort Down’.
8. Go to ‘File’  Click ‘Export Data’. This will copy the data into an excel spreadsheet.
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Figure B.1: An example of image analysis to calculate the area of GFAP- staining
showing data export from Image Pro 7 to Microsoft Excel.

APPENDIX C
CELL CULTURE AND MEDIA PREPARATION
C.1

Rat Primary Cervical Disarticulation:

Use a fresh 50 ml tube with 15 ml media and 750µl penicillin-streptomycin (PS)
to collect tissue.
C.1.1

Materials Needed for Dissection:
1. Large petri dish
2. Diapers
3. Empty yellow-tip containers
4. Plastic bag
5. Cervical Scissors
6. Micro-scissors
7. Curve tip scissors
8. Small tip forceps
9. Large forceps
10. Small spatula
11. Full wash bottle with 70% Isopropyl alcohol
12. 50ml centrifuge tubes with 40ml basal media eagle (BME)
13. 50ml centrifuge tube with 10ml BME and 0.05% PS (one for every 7 pups)
14. Box of gloves
15. 50ml centrifuge tube holder
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16. Beaker of ice
C.1.2

Set-up for Dissection:
1. Soak the dissection instruments with 70% isopropyl alcohol in a container.
2. Place the pups in the yellow container and set them on one end of the
dissection table.
3. Place three diapers on the dissection table.
4. Place one large petri dish under the microscope and pour ~10ml BME and PS
into it.
5. Place another petri dish about seven inches away from the dish under the
microscope to be used for waste.
6. Place and keep the plastic bag near the diapers.
7. Place the 50ml centrifuge tube holder on the dissection table next to the
alcohol.
8. Place the wash bottle next to the utensils.
9. Keep the basal media, gloves, and other supplies on the cart.
10. Place over-head lighting and stereoscope in position above the centered dish.

C.1.3

Dissection Protocol:
1. Put on a pair of gloves.
2. Remove one pup from the box by pinching the skin above the spine near the
lower back and set the pinkie on a diaper.
3. Spray pup with alcohol and pick up again using the pinch method.
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4. Quickly set cervical scissors behind the ear being cautious of paws and make
one very quick and decisive cut. (Dip scissors in alcohol and place it on a clean
diaper)
5. Blot the head at the point of disarticulation on a diaper and discard the body in
the plastic bag.
6. Using the micro-scissors, cut the skin in an upward motion then dip scissors in
alcohol (This should expose the skull).
7. Cut the skull using the same upward motion (this should expose the brain)
8. Using large forceps, curl back both sides of the skull to better expose the brain
then use a spatula to scoop out the brain into the basal media in the petri dish.
9. Remove the cerebellum at the demarcation line and place it in the waste dish.
10. Keep the brain in place with large forceps and remove meninges and blood
vessels with small forceps. Place the waste into the waste dish.
11. Once all blood vessels and meninges are removed, place tissue into a 50 ml
tube.
12. Repeat steps 2-11 until all pups are sacrificed.
13. Discard all waste into the freezer room and clean all utensils.
C.1.4

Materials Needed for Tissue Culture:
1. T25 cell culture flask
2. Bucket of ice
3. Neuronal Culture Media
4. Trypsin EDTA

131
C.1.5

Cell Harvest Protocol:
1. Aspirate harvested brain tissue with a 10ml pipette into a 15 ml tube.
2. Add 4ml of complete NCM and 1ml trypsin brain tissue then triturate about 15
times.
3. Let the brain tissue settle by placing it into a large beaker of ice for 5 minutes.
4. The supernatant contains the neuronal cells. Remove the supernatant and place
it into another sterilized 15 ml centrifuge tube and place on ice.
5. Repeat steps 2-4 two more times.
6. Centrifuge and follow protocol to count and plate cells in the cell culture flask.
C.2

C.2.1

Protocol for Isolation of BMVECs from Glial Cells

Materials Required
1.Primary culture (washed at least 1 time)
2.Puromycin (10mg/ml)

C.2.2

Protocol
1. Add 3ug/ml concentration of puromycin to the primary culture
For 3 flasks, perform the following dilution:
Add 4.5ul of puromycin to 15ml astrocyte media. Mix well by inverting the tube.
Suck out the media from flasks. Add 5ml of mixed solution to each flask
Place the flasks in the incubator for 48h
Suck out all the media and dead cells.
Add 4ml of endothelial media to each flask.
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C.3
C.3.1

Rat Brain Endothelial Media

Materials Required for 250 mL Media



Sterile filtration unit



233.75 mL Rat Brain Endothelial Cell Basal Media



15 mL Rat Brain Endothelial Growth Factor (6.0 %)



1.25 mL Penicillin/Streptomycin solution (P/S) (0.5 %)

C.3.2

Preparation of Rat Brain Endothelial Media

The procedure is carried out in a laminar flow hood (sterile environment).
1. Add 100 mL Rat Brain Endothelial Cell Basal Media to the sterile filtration unit.
2. Add Rat Brain Endothelial Growth Factor and P/S to the sterile filtration unit.
3. Add 133.75 mL Ham’s F-12K media to the sterile filtration unit.
4. Place the lid over the sterile filtration unit and connect it to the vacuum nozzle.
5. Carefully turn on the vacuum and allow the liquid to pass through the filter. Make
sure to hold the sterile filtration unit during this step so the unit does not turn
over. Turn off the vacuum before bubbles form.
6. Twist the top of the filtration unit off carefully. Screw the sterile cap onto the
container of media.
Label media as Endothelial media with the date and your initials, and store in the
refrigerator.
C.4
C.4.1

Astrocyte Media

Materials Required for 250 mL Media



Sterile filtration unit



223.75 mL Ham’s F-12K media with L-Glutamine
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12.5 mL Fetal Bovine Serum (FBS) (5.0 %)



12.5 mL Horse Serum (5.0 %)



1.25 mL Penicillin/Streptomycin solution (P/S) (0.5 %)

C.4.2

Preparation of Astrocyte Growth Media

The procedure is carried out in a laminar flow hood (sterile environment).
7. Add 100 mL Ham’s F-12K media to the sterile filtration unit.
8. Add Fetal Bovine Serum, Horse Serum, and P/S to the sterile filtration unit.
9. Add 123.75 mL Ham’s F-12K media to the sterile filtration unit.
10. Place the lid over the sterile filtration unit and connect it to the vacuum nozzle.
11. Carefully turn on the vacuum and allow the liquid to pass through the filter. Make
sure to hold the sterile filtration unit during this step so the unit does not turn
over. Turn off the vacuum before bubbles form.
12. Twist the top of the filtration unit off carefully. Screw the sterile cap onto a
container of media.
13. Label media as Astrocyte media with the date and your initials, and store in the
refrigerator.
C.5
C.5.1

CRL-2303 Media

Materials Required for 250 mL Media



Sterile filtration unit



221.25 mL Dulbecco’s Modified Eagle’s Medium (DMEM)



25 mL Fetal Bovine Serum (FBS) (10 %)



2.5 mL Amino acid solution (1 %)



1.25 mL Penicillin/Streptomycin solution (P/S) (0.5 %)
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C.5.2

Preparation of CRL-2303 Growth Media

The procedure is carried out in a laminar flow hood (sterile environment).
1. Add 110.25 mL DMEM to the sterile filtration unit.
2. Add Fetal Bovine Serum, Amino acid solution, and P/S to the sterile filtration
unit.
3. Add 111 mL DMEM to the sterile filtration unit.
4. Place the lid over the sterile filtration unit and connect it to the vacuum nozzle.
5. Carefully turn on the vacuum and allow the liquid to pass through the filter. Make
sure to hold the sterile filtration unit during this step so the unit does not turn
over. Turn off the vacuum before bubbles form.
6. Twist the top of the filtration unit off carefully. Screw the sterile cap onto a
container of media.
7. Label media as CRL-2303 media with the date and your initials, and store in the
refrigerator.
C.6
C.6.1

Locke’s solution

Materials Required for 250 mL Media



2250 mg of Sodium Chloride (NaCl) (154 mM)



104.4 mg of Potassium Chloride (KCl) (5.6 mM)



75.6 mg of Sodium Bicarbonate (NaHCO3) (3.6 mM)



84.5 mg of Calcium Chloride (CaCl2.2H2O) (2.3 mM)



252.3 mg of Glucose (5.6 mM)
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1.25 mL of 1M stock 4-(2-hydroxyethyl)-2-piperazineethanesulfonic acid
(HEPES) (pH 7.4) (5 mM)



248.75 mL of purified water

C.6.2 Preparation of Locke’s Solution
1. Dissolve the components in 100 mL of purified water and add them to the vacuum
filtration unit.
2. Add 100 mL of purified water to the vacuum filtration unit.
3. Add water with dissolved components.
4. Add 1.25 mL of 1 M stock HEPES.
5. Add the remaining amount of purified water.
6. Place cap on the unit. Carefully turn on the vacuum.
7. Allow all the liquid to pass through the filter. Turn off the vacuum before bubbles
form.
8. Twist the top of the vacuum unit off carefully. Screw the sterile cap onto the
container of the solution.
9. Label as Locke’s solution with the date and your initials, and store in the
refrigerator.
Note: For preparing Locke’s solution without sodium, replace the Sodium Chloride
with the same molarity of Choline Chloride. We don’t have any account for Sodium
Bicarbonate.
C.7
C.7.1

Fluo3/AM Loading:

Materials Needed for 2ml Imaging Solution:

1. 2µl Pluronic acid
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2. 4µl Fluo 3/AM 3. 2ml Locke’s Solution (pre-warmed in an incubator for at least 15
minutes)
C.7.2

Protocol

1. Turn off the light of the cell culture hood
2. Warm all components to room temperature before the experiment.
3. Add 2ml of pre-warmed Locke’s solution to a 15 ml centrifuge tube
4. Add 2µl pluronic acid to the tube then mix (vortex until soapsuds are observed)
5. Add 4µl Fluo3/AM (2mg/ml in DMSO) and cap the tube.
6. Mix the contents of the tube by gently inverting it two or three times.
7. Remove all media from one well then add ~500µl of loading solution to the
emptied well.
8. Repeat step seven for all the wells to be imaged.
9. Place the cell into the incubator and allow the dye to enter the cells for 45 minutes
to an hour.
10. Remove the loading solution and allow the cells to recover in 475µl of Locke’s
solution for 30 minutes then the cells are ready for imaging.

APPENDIX D
SPLITTING AND FREEZING CELLS
D.1

Splitting Cells or Re-plating Cells

1.

Remove media from cells into a waste beaker.

2.

Wash flask once with 3 mL of 1X PBS (1 mL 10X PBS + 9 mL sterile water gives
10 mL 1X PBS). Pipet PBS gently into a flask. Lay flask down once. Lift flask and
remove PBS.

3.

Add 1.5 mL (for CRL-2303 and Microglia) or 3 mL (for Astrocytes) thawed
trypsin/EDTA to flask. Cap the flask and put it in the incubator for 3 minutes (for
CRL-2303 and Microglia) or 8 minutes (for Astrocytes). Take the flask out of the
incubator and check under the microscope to ensure cells are detached.

4.

Add 3 mL fresh media to the flask and transfer them to a 15 ml centrifuge tube.

5.

Centrifuge cells in a tube using a counterbalance in a pre-cooled centrifuge (8°C) at
160 r.c.f. (relative centrifugal force) for 8 minutes.

6.

After spinning, remove the supernatant liquid into the waste beaker.

7.

Suspend pellet in the desired amount of media, then vortex until cells are evenly
distributed throughout media.

8.

Before plating, count the number of cells using a hemocytometer.

9.

Plate cells onto the flask, adding the appropriate amounts of media.
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10. Label flask with cell name, date, and passage number (passage number increases
after splitting cells).
D.2

Freezing Cells

1. Remove media from cells into a waste beaker.
2. Wash flask once with 3 mL of 1X PBS (1 mL 10X PBS + 9 mL sterile water gives 10
mL 1X PBS). Pipet PBS gently into a flask. Lay flask down once. Lift flask and
remove PBS.
3. Add 1.5 mL (for CRL-2303 and Microglia) or 3 mL (for Astrocytes) thawed
trypsin/EDTA to flask. Cap the flask and put it in the incubator for 3 minutes (for
CRL-2303 and Microglia) or 8 minutes (for Astrocytes). Take the flask out of the
incubator and check under the microscope to ensure cells are detached.
4. Add 3 mL fresh media to the flask and transfer them to a 15 ml centrifuge tube.
5. Centrifuge cells in a tube using a counterbalance in a pre-cooled centrifuge (8°C) at
160 r.c.f. (relative centrifugal force) for 8 minutes.
6. After spinning, remove the supernatant liquid into the waste beaker.
7. Suspend pellet in the desired amount of media, then vortex until cells are evenly
distributed throughout media.
8. Add 5% DMSO dropwise to cells. Mix by inverting centrifuge tube.
9. Transfer cell mixture to a pre-cooled cryovial.
10. Label cryovial with cell name, date, and passage number (passage number is the
same as on the flask).
11. Put cryovials in a container and place in a -80°C freezer overnight.
12. Transfer cells into liquid nitrogen. Record the cane number.

APPENDIX E
THAWING AND FEEDING CELLS
E.1

Thawing Cells

1. Remove the vial of cells from liquid nitrogen and immediately place in a water bath
preheated to 37°C.
2. Thaw the vial containing cells quickly (approximately three minutes).
3. Remove the vial, wipe the vial with Kim wipe, and isopropanol under the laminar
flow hood.
4. Mix cell suspension by pipetting up and down the vial. Do not vortex cells.
5. Gently transfer the cells suspension from the vial into a flask with 5 mL pre-warmed
cell growth media.
6. Label flask with cell type, date, and passage number (passage number increases when
thawing cells.
7. Incubate the cells for 24 hr at 37°C in a 5% CO 2 incubator.
8. Do not use the cells immediately after thawing as it contains Dimethyl Sulfoxide
(DMSO) and some dead cells. Passage them at least once before seeding the cells.
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E.2

Feeding Cells

1. Remove 3 mL media from 24 cm2 flask into a waste beaker.
2. Add 3 mL pre-warmed cell culture media to cells.
3. Label flask with the date of feeding.
4. Place the flask back into the incubator.

APPENDIX F
FIXING CELLS
Protocol for fixation is explained in the following steps:
1. Remove complete media from cell culture.
2. Wash the cells with pre-warmed Locke’s solution.
3. Add the fixing solution (Diff Quik from Siemens) to cover the whole surface of
the well or dish and leave it for 10 minutes.
4. Remove the fixing solution and add Phosphate Buffer Saline (PBS) to cover the
whole surface.
5. For storage, label the plate or dish, seal with parafilm and keep it at 2-8°C (in a
refrigerator).
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APPENDIX G
STAINING PROTOCOLS
G.1

DAPI Staining Protocol

1. A 14.27 millimolar concentration of DAPI in DI water was diluted 1 to 1000 in 1x PBS.
2. Once DAPI has been added place the dish in a 37ºC incubator for 10 minutes
(depending on the health of the cells you may need a longer time to load to do to the
fact that healthy cells take longer to load DAPI than damaged or dead cells).
G.2

Diff-Quik Staining Protocol

1. PBS was aspirated out from the fixed plate.
2. Add 350 µl of Solution I (orange in color) from the Diff Quik staining kit to each well.
3. Wait for 5 to 10 minutes.
4. Take out all of Solution I from the wells and add 350 µl of Solution II (blue), from the
staining kit to each well.
5. Wait for 5 to 10 minutes.
6. Take out all of Solution II from the wells.
7. Wash 2/3 times with clean deionized water.
8. Observe staining under the phase microscope and wash more if necessary (the staining
is looking too dark).
9. Take images under the microscope.
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G.3

VWF Antibody (Ab) Staining

1. Fixation of Cells:


Remove complete media from cell culture.



Wash twice the cells with pre-warmed phenol red-free RPMI solution.



Add 1X fixative ( ) to cover the whole surface of the well or dish and keep it for 5
minutes.



Remove methanol and add 1X PBS to cover the whole surface.



For storage seal the plate or dish with paraffin and keep it at 2-8 ºC (in a
refrigerator).

2. Permeabilization of cells: Remove PBS from pre-fixed cells and 0.2 % Triton X 100
(in 1X PBS) to cover the whole surface and keep it at room temperature for 15 minutes.
3. Blocking: Remove Triton X 100 and add 5% Goat Serum (in 1X PBS) to cover the
whole surface. Seal the plate or dish with paraffin and keep it at 2-8 ºC (in a refrigerator)
for 4-5 hrs or overnight.
4. Primary Ab: Remove goat serum and add 1° Ab (Rabbit X factor VIII in 1:500 1X
PBS) to cover the whole surface. Seal the plate or dish with paraffin and keep it at 2-8
ºC (in a refrigerator) for 24 hrs or overnight.
5. Washing: Remove 1° Ab and wash twice with 1X PBS.
6. Secondary Ab: Add 2° Ab (1:500 Goat Anti- Rabbit Ig Ab in 2% Goat Serum which is
in 1X PBS) to cover the whole surface. Seal the plate or dish with paraffin and cover
with aluminum foil and keep it at room temperature for 45-60 minutes.
7. Washing: Remove 2° Ab and wash twice with 0.2 % Triton X 100 (in 1X PBS). Lastly,
add 1X PBS to cover the whole surface.
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8. Fluorescence Microscopy: Observe staining using a fluorescent microscope.
9. Storage: Seal the plate or dish with paraffin and cover with aluminum foil and keep it
at 2-8 ºC (in a refrigerator) for storage for weeks.
G.4

GFAP Antibody (Ab) Staining

1. Fixation of Cells:


Remove complete media from cell culture.



Wash twice the cells with pre-warmed Locke’s solution.



Add ice-cold methanol to cover the whole surface of the well or dish and keep it
for 5 minutes.



Remove methanol and add 1X PBS to cover the whole surface.



For storage seal the plate or dish with paraffin and keep it at 2-8 ºC (in a
refrigerator).

2. Permeabilization of cells: Remove PBS from pre-fixed cells and 0.2 % Triton X 100
(in 1X PBS) to cover the whole surface and keep it at room temperature for 15 minutes.
3. Blocking: Remove Triton X 100 and add 2% Goat Serum (in 1X PBS) to cover the
whole surface. Seal the plate or dish with paraffin and keep it at 2-8 ºC (in a refrigerator)
for 4-5 hrs or overnight.
4. Primary Ab: Remove goat serum and add 1° Ab (Anti-GFAP produced in rabbit in
1:500 1X PBS) to cover the whole surface. Seal the plate or dish with paraffin and keep
it at 2-8 ºC (in a refrigerator) for 24 hrs or overnight.
5. Washing: Remove 1° Ab and wash twice with 1X PBS.
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6. Secondary Ab: Add 2° Ab (1:500 Goat Anti- Rabbit Ig Ab in 2% Goat Serum which is
in 1X PBS) to cover the whole surface. Seal the plate or dish with paraffin and cover
with aluminum foil and keep it at room temperature for 45-60 minutes.
7. Washing: Remove 2° Ab and wash twice with 0.2 % Triton X 100 (in 1X PBS). Lastly,
add 1X PBS to cover the whole surface.
8. Fluorescence Microscopy: Observe staining using a fluorescent microscope.
9. Storage: Seal the plate or dish with paraffin and cover with aluminum foil and keep it
at 2-8 ºC (in a refrigerator) for storage for weeks.

APPENDIX H
MTT ASSAY PROTOCOL
400 µL of MTT solution is added into each well of a 24 well plate. Considering this, 9.6
mL of MTT would be needed to treat an entire plate. Usually, 11 mL of solution is
prepared to have a buffer volume.
Procedure for a 24 well plate:
1. Weigh 13.75 mg of MTT powder and add it to 11 mL of prewarmed DMEM
without phenol red (or sterile Locke’s solution).
2. Media is aspirated from the wells carefully. Do not wash.
3. Add 400 uL of MTT solution carefully to each well from the side.
4. Place the 24 well plates in the incubator for 60 minutes to allow the cells to react
with the MTT solution.
5. The viable cells react, and purple crystals are formed in the wells.
6. After incubation, aspirate the MTT solution carefully without lifting the crystals
and add 300 µL of 91% isopropanol to each well.
7. Allow the crystals to be dissolved into the isopropanol, gently shake the well
plate. Don’t delay after adding the isopropanol as it will evaporate.
8. Transfer 300 µL of isopropanol with dissolved crystals into 96 well plates.
9. Measure the plate using a spectrophotometer at a wavelength of 570 nm.
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APPENDIX I
NO ASSAY PROTOCOL
I.1

Materials Required
Griess Reagent:
i)

N-(1-naphthyl)ethylenediamine (Component A), , 25 mL of a
0.1% (1 mg/mL) solution, sealed under argon

ii)

Sulfanilic acid (Component B), 25 mL of a 1% (10 mg/mL)
solution in 5% phosphoric acid

iii)

Nitrite standard solution (Component C), 1.0 mL of 1.0 mM
sodium nitrite in deionized water

I.2

Protocol
1. Mix the following in a 1.5 or 2mL Eppendorf tube for preparing a solution of 1
mL for each sample.
i)

866.5 µL of non-sterile water

ii)

100 µL of media from the cells

ii)

33.5 µL of Griess Reagent (A and B in equal volume)

2. Prepare a photometric reference sample by using the Nitrite standard solution
(Component C) of Griess Reagent (as shown in step 1, replacing the media (ii)
with different concentrations of Component C).
3. Vortex each mixture for a few seconds.
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4.

Incubate the mixture for 30 minutes in dark at room temperature.

5. Measure the absorbance of the nitrite-containing sample at 548 nm relative to the
reference sample.
6. Convert absorbance readings to nitrite concentrations.
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